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A B S T R A C T
Background
Drug resistance is common in focal epilepsy. In this update, we summarised the current evidence regarding add-on levetiracetam in treating
drug-resistant focal epilepsy. The original review was published in 2001 and last updated in 2012.
Objectives
To evaluate the eGectiveness of levetiracetam when used as an add-on treatment for people with drug-resistant focal epilepsy.
Search methods
We searched the Cochrane Register of Studies (CRS Web, which includes the Cochrane Epilepsy Group Specialized Register and CENTRAL),
MEDLINE Ovid, ClinicalTrials.gov, and the WHO International Clinical Trials Registry Platform (ICTRP) to November 2018. We contacted the
manufacturers of levetiracetam and researchers in the field to seek any ongoing or unpublished trials.
Selection criteria
Randomised, placebo-controlled trials of add-on levetiracetam treatment in people with drug-resistant focal epilepsy.
Data collection and analysis
Two review authors independently selected trials for inclusion, assessed trials for bias, extracted data, and evaluated the overall certainty
of the evidence. Outcomes investigated included 50% or greater reduction in focal seizure frequency (response), treatment withdrawal,
adverse eGects (including a specific analysis of changes in behaviour), cognitive eGects, and quality of life (QoL). Primary analysis was
intention-to-treat. We performed meta-analysis for all outcomes using a Mantel-Haenszel approach and calculated risk ratios (RR), with
95% confidence intervals (CI) for all estimates apart from adverse eGects (99% CIs). We assessed heterogeneity using a Chi2 test and the
I2 statistic.
Main results
This update included 14 trials (2455 participants), predominantly possessing low risks of bias. Participants were adults in 12 trials (2159
participants) and children in the remaining two (296 participants). The doses of levetiracetam tested were 500 mg/day to 4000 mg/day
in adults, and 60 mg/kg/day in children. Treatment ranged from 12 to 24 weeks. When individual doses were examined, levetiracetam at
either 500 mg/day or 4000 mg/day did not perform better than placebo for the 50% or greater reduction in seizure frequency outcome (500
mg: RR 1.60, 95% CI 0.71 to 3.62; P = 0.26; 4000 mg: RR 1.64, 95% CI 0.59 to 4.57; P = 0.34). Levetiracetam was significantly better than placebo
at all other individual doses (1000 mg to 3000 mg). RR was significantly in favour of levetiracetam compared to placebo when results were
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pooled across all doses (RR 2.37, 95% CI 2.02 to 2.78; 14 studies, 2455 participants; moderate-certainty evidence). Dose–response analysis
demonstrated that the odds of achieving response (50% or greater reduction in seizure frequency) were increased by nearly 40% (odds
ratio (OR) 1.39, 95% CI 1.23 to 1.58) for each 1000 mg increase in dose of levetiracetam. There were important levels of heterogeneity across
multiple comparisons.
Participants were not significantly more likely to experience treatment withdrawal with levetiracetam than with placebo (pooled RR 1.11,
95% CI 0.89 to 1.40; 13 studies, 2428 participants; high-certainty evidence).
Somnolence was the most common adverse eGect, aGecting 13% of participants, and it was significantly associated with levetiracetam
compared to placebo (pooled RR 1.62, 99% CI 1.19 to 2.20; 13 studies, 2423 participants; moderate-certainty evidence). Changes in
behaviour were negligible in adults (1% aGected; RR 1.79, 99% CI 0.59 to 5.41), but significant in children (23% aGected; RR 1.90, 99% CI
1.16 to 3.11). Levetiracetam had a positive eGect on some aspects of cognition and QoL in adults and worsened certain aspects of child
behaviour.
Authors' conclusions
Overall, this review update finds that in both adults and children with drug-resistant focal epilepsy, levetiracetam added on to usual care
is more eGective than placebo at reducing seizure frequency, it is unlikely to be stopped by patients, and it has minimal adverse eGects
outside of potential worsening behaviour in children. These findings are unchanged from the previous review update in 2012. This review
update contributes two key additional findings: 1. a 500 mg daily dose of levetiracetam is no more eGective than placebo at reducing
seizures; and 2. the odds of response (50% reduction in seizure frequency) are increased by nearly 40% for each 1000 mg increase in dose
of levetiracetam.
It seems reasonable to continue the use of levetiracetam in both adults and children with drug-resistant focal epilepsy.
P L A I N   L A N G U A G E   S U M M A R Y
Levetiracetam add-on for drug-resistant focal epilepsy
This is an updated version of the Cochrane Review first published in 2001 and last updated in Issue 9, 2012 of the Cochrane Database of
Systematic Reviews.
Background and objective
Epilepsy is a one of the most common disorders of the brain, aGecting over 70 million people worldwide. Levetiracetam is an antiepileptic
drug widely used around the world. In this review, we summarised the current evidence regarding its eGectiveness when used as a
treatment added on to usual care in people experiencing focal epilepsy that responds poorly to medication.
Methods
The evidence is current to 26 November 2018. Fourteen studies in which people were randomly assigned to either levetiracetam or a dummy
tablet (placebo) were included, with a total of 2455 participants (296 of whom were children). Everybody had their usual medications
continued, meaning that nobody was leQ without taking an antiepileptic medicine. Among other things, we looked at how many people
had their frequency of seizures reduced by 50% or more when taking levetiracetam versus when taking the placebo tablet. We combined
the results of all of these people in order to increase our confidence in how eGective levetiracetam is.
Key results
Levetiracetam significantly reduced the frequency of seizures in both adults and children. Just over half of children responded to
levetiracetam, and 34% of adults also responded. These responses were much higher than in the placebo groups, indicating that
levetiracetam was better than placebo. The most eGective doses were those of 1000 mg to 3000 mg levetiracetam. For every 1000 mg
increase in dose, the chances that levetiracetam would reduce seizures (fits) appeared to improve by 40%. We noticed that the results were
very diGerent in each study we looked at. Therefore, although we could see that levetiracetam works, it was diGicult for us to be certain
about how large that eGect actually is.
Levetiracetam was generally tolerated well by adults and children. Most people managed to complete their course of levetiracetam
during the studies. There were very few side eGects with levetiracetam. The only side eGect that was significantly associated with
levetiracetam was somnolence (sleepiness). However, we also noticed that the behaviour of some children taking levetiracetam could
worsen significantly.
Overall, it seems reasonable to add levetiracetam to a patient's usual antiepileptic medications if they have focal epilepsy that has
responded poorly to other medications.
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S U M M A R Y   O F   F I N D I N G S
 
Summary of findings 1.   Levetiracetam compared to placebo for drug-resistant focal epilepsy
Levetiracetam compared to placebo for drug-resistant focal epilepsy























Study population50% or greater reduction in focal seizure fre-
quency (responders) intention to treat – all









The odds of response (50%
reduction in seizure frequen-
cy) was increased by near-
ly 40% (OR 1.39, 95% CI 1.23
to 1.58) for each 1000 mg in-
crease in dose of levetirac-
etam.
Study populationTreatment withdrawal – all doses








There was no effect on the
odds of withdrawal of treat-
ment (OR 0.99, 95% CI 0.85
to 1.15) for each 1000 mg in-
crease in dose of levetirac-
etam.
Study populationAdverse effects: 5 most common adverse ef-
fects (any age) – somnolence










Study populationAdverse effects: 5 most common adverse ef-
fects (any age) – headache









Adverse effects: 5 most common adverse ef-
fects (any age) – dizziness












































































































































Study populationAdverse effects: 5 most common adverse ef-
fects (any age) – fatigue (asthenia)










Study populationAdverse effects: 5 most common adverse ef-
fects (any age) – accidental injury









*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: confidence interval; OR: odds ratio; RCT: randomised controlled trial; RR: risk ratio.
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
aDowngraded one level due to inconsistency: potentially important heterogeneity present between studies (I2 > 45%).
bHigh or unclear risk of bias present in 9/14 studies. However, sensitivity analysis restricted to studies of low risk of bias only showed similar numerical results and no changes
to conclusions. Therefore, no downgrade for risk of bias.
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B A C K G R O U N D
This is an update to a Cochrane Review that was originally
published in 2001 (Chaisewikul 2001), and last updated in 2012
(Mbizvo 2012).
Description of the condition
Epilepsy is a one of the most common disorders of the brain,
aGecting over 70 million people worldwide. Generally, it is defined
as two or more unprovoked seizures occurring more than 24
hours apart, a single unprovoked seizure if recurrence risk is
high (a greater than 60% risk over the next 10 years), or the
specific diagnosis of an epilepsy syndrome (Fisher 2015). In
2017, the International League Against Epilepsy (ILAE) updated
the classification and terminology of seizures and epilepsy to
incorporate progress in our understanding of epilepsy since the
original 1989 classification and subsequent 2010 revision (Berg
2010; Fisher 2017a; Fisher 2017b; ScheGer 2017). There are now
four levels in which a diagnosis of epilepsy can be characterised,
and these allow for the varying availability of diagnostic resources
worldwide (Fisher 2017a; Fisher 2017b; ScheGer 2017). A level
one diagnosis requires a clinician to recognise that a person has
had two or more unprovoked seizures, rather than some other
types of paroxysmal events. A level two diagnosis subclassifies
the epilepsy based on seizure type, where the 'focal' and
'generalised' seizure categories are now supplemented with the
two additional categories 'generalised and focal epilepsy' and
'unknown if generalised or focal epilepsy'. These recognise that
not all epilepsies can be dichotomised into the simple forms of
focal or generalised. A level three diagnosis subclassifies epilepsy
by syndrome (e.g. Dravet syndrome, West syndrome, or Lennox-
Gastaut syndrome). A level four diagnosis subclassifies epilepsy by
aetiology, and can include complex diagnostic information from
neuroimaging, genetics, immunology, and environmental factors
(Fisher 2017a; Fisher 2017b; ScheGer 2017).
People with epilepsy not only suGer from the direct consequences
of seizures, which include injuries, infections (such as aspiration
pneumonia), and death (including a 1% risk of sudden
unexpected death in epilepsy), but they also experience multiple
neurobiological, cognitive, and psychosocial complications of
epilepsy. Low- and middle-income countries contribute nearly 80%
of the global burden of epilepsy. This is largely due to the presence
of tropical infections such as neurocysticercosis associated with
poorer standards of hygiene and health care, and also because
there tends to be a large number of children among these
populations (Shorvon 1996). The incidence of epilepsy peaks in
early childhood before falling to low levels in early adult life and
then rising again among the elderly population (Shorvon 1996).
Therefore, epilepsy remains a significant burden of disease in
high-income countries not least because of the ageing population
structure. The UK National General Practice Study of Epilepsy
found that of the 60% of people with epilepsy who have motor
seizures, focal-onset epilepsy is more common than generalised-
onset epilepsy, aGecting two-thirds and one third of the people,
respectively (NICE 2012).
The goal of epilepsy treatment is to achieve sustained seizure
freedom and to achieve this using a tolerated antiepileptic
drug (AED) schedule. Unfortunately, over 75% of people with
epilepsy remain untreated and this is mostly resultant from
the concentration of epilepsy within low- and middle-income
countries. Surprisingly, many people in low-income countries
enter long-term remission from their epilepsy without AEDs,
suggesting that a drug-independent mechanism to long-term
remission may exist. However, it is doubtless that the use of
AEDs is associated with favourable outcomes for people with
epilepsy. Various combinations of AEDs can be used to try and
achieve those outcomes, with varying success rates. The prognosis
in newly diagnosed epilepsy is usually good, with up to 50%
of people entering remission (seizure-freedom for five years on
or oG treatment) either without treatment or on their first AED
(Brodie 2010; Maguire 2011). An additional 10% achieve remission
on a second or third drug (Brodie 2010). For the remainder, AEDs
may fail to provide remission from seizures. Pharmacoresistance
or intolerable drug-related adverse eGects, or both, are major
contributors to this. Drug-resistant epilepsy is defined by the ILAE
as that in which there has been failure of adequate trials of
two tolerated and appropriately chosen and used AED schedules
(whether as monotherapies or in combination) to achieve sustained
seizure freedom (Kwan 2010). No seizure frequency requirement is
necessary to meet this definition. This allows for those people with
infrequent seizures (e.g. occurring once a year) to still be regarded
as drug-resistant, which is relevant to the impact seizures have on
lifestyle factors such as driving.
Description of the intervention
Levetiracetam is one of a second generation of AEDs introduced in
the late 1990s to early 2000s. It is extensively used worldwide and in
all ages for the treatment of drug-resistant focal epilepsy and other
types of epilepsy (Lyseng-Williamson 2011). A third generation
of AEDs has been introduced more recently, since approximately
2010, and these include levetiracetam's newer selective analogue
brivaracetam, and others such as eslicarbazepine, perampanel,
and vigabatrin (Coppola 2017; Hanaya 2016). However, the second
generation is broadly considered the first line of AED therapy in
routine clinical practice. This is because there is extensive evidence
that these drugs are generally well tolerated (more so than the
first generation of AEDs such as phenytoin, carbamazepine, and
sodium valproate), and they are largely non-inferior to both
first- and third-generation AEDs (although formal head-to-head
comparisons remain scarce) (Hanaya 2016). Even since the last
update to this review in 2012, levetiracetam has established itself
as one of the most popular AED options in routine clinical practice.
This is largely because outside of its clinical eGicacy in reducing
seizures, particularly favourable adverse eGects profile, limited
interaction with other drugs, and ability to be uptitrated rapidly
(Gambardella 2008). These make it an uncomplicated option for
clinicians to use. However, it remains important that the evidence
base behind its use is kept up-to-date, both in terms of eGicacy
and also in terms of adverse events, so that frontline clinicians
are able to help patients come to the most accurately informed
decision about their therapy. This information is particularly
pressing now given the availability of a host of third-generation
AED options available for patients to choose. Furthermore, in
the absence of formal head-to-head comparisons of levetiracetam
against other AEDs, updated systematic review information on its
eGicacy is likely to be important for ongoing network meta-analyses
comparing levetiracetam and other AEDs to a common reference
AED treatment.
Levetiracetam was first introduced onto the market in April 2000.
It has been available as a generic brand in the US since 2008 and
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in the UK since 2011 (Mbizvo 2012). The drug is available for use by
mouth or intravenous infusion. For oral use in adults aged 16 years
and over, it is given at an initial dose of 250 mg once daily for one
to two weeks, then increased to 250 mg twice daily, then increased
in steps of 250 mg twice daily (with the maximum per dose being
1.5 g twice daily), adjusted according to response, with dose to be
increased every two weeks (BNF 2019a). Titration can be performed
more quickly than this in emergency circumstances. For oral use in
children under 16 years of age, it is given at an initial dose of 7 mg/
kg to 10 mg/kg once daily, then increased in steps of up to 7 mg/kg
to 10 mg/kg twice daily (maximum per dose 30 mg/kg twice daily),
with dose to be increased every two weeks (BNF 2019b).
Levetiracetam is only licensed for use in the following
circumstances for adults and children by mouth or intravenous
infusion: as either monotherapy or add-on therapy for focal-onset
seizures with or without evolution to bilateral tonic-clonic seizures,
and as add-on therapy for generalised-onset motor seizures
(including myoclonic seizures and tonic-clonic seizures) (BNF
2019a). However, in routine clinical practice, it is now popular as an
unlicensed monotherapy for generalised-onset motor seizures also,
particularly as a less teratogenic alternative to sodium valproate
in women of childbearing age with epilepsy (Tomson 2015). It is
also now used frequently as an unlicensed intravenous treatment
option in status epilepticus (Cock 2011). A discussion on the
unlicensed or intravenous use of levetiracetam is outside of the
scope of this current review. This review focuses on updating
the evidence base surrounding oral levetiracetam use as add-
on therapy in drug-resistant focal epilepsy. The review will draw
information from randomised, placebo-controlled trials of add-on
levetiracetam treatment in people (of any age) with drug-resistant
focal epilepsy.
How the intervention might work
Levetiracetam possesses both antiepileptic and anti-epileptogenic
properties (Betts 2000). Its exact mode of action is not completely
understood (Xiao 2009). It binds to, and modulates, the synaptic
vesicle protein 2A (SV2A); a protein that has some controlling
eGect on neurotransmitter release from presynaptic vesicles
(Gillard 2006; Lynch 2004). It also selectively inhibits N-type Ca2+
channels and decreases intracellular calcium-ion increase (both
of which negatively impact neurotransmitter release) (Lukyanetz
2002; Niespodziany 2001). There is evidence that it releases γ-
aminobutyric acid (GABA) activity and glycine-gated currents by
acting on their negative allosteric modulators, namely zinc and
the beta-carbolines (Rigo 2002). Neuroprotective eGects have also
been described (Gibbs 2006). The proposed mechanisms of action
of levetiracetam have been largely derived from animal-model
studies, and the results remain to be validated in humans.
With regard to pharmacokinetics, levetiracetam generally
demonstrates a favourable profile. Bioavailability is the fraction of
a drug's administered dose that reaches the systemic circulation.
When a drug is administered orally, bioavailability can be
reduced by factors such as the rates of absorption and first-
pass gut and hepatic metabolism. Oral levetiracetam provides
close to 100% bioavailability, making it largely bioequivalent to
intravenous levetiracetam (Trinka 2011). A drug's susceptibility to
oxidative hepatic metabolism and its influence on cytochrome
P450 enzyme function in the liver can largely determine the
duration and intensity of the pharmacological action of that
drug, and its interaction with other drugs. Levetiracetam is
advantaged by a lack of oxidative hepatic metabolism or influence
on cytochrome P450 enzyme function. Dosing is thus simplified
in both adults and children by linear, dose-proportional kinetics.
Plasma concentrations of levetiracetam peak at one hour, and a
steady-state concentration is reached by 48 hours with repeated
dosing (usually twice daily). The drug shows no significant
pharmacokinetic interactions with other AEDs or with drugs such as
warfarin, digoxin, and the oral contraceptive pill; which all interact
with the aforementioned hepatic enzyme systems. Clearance of
levetiracetam is exclusively renal: 66% unchanged and 24% as an
inactive metabolite following hydrolysis of its acetamide group
in the blood. Clearance is 30% to 40% higher in children and it
is impaired in elderly people or in people with renal impairment
(Crepeau 2010; Glauser 2006; Pellock 2001). Dose lowering is
required in renal impairment: in adults, at a maximum of 2000 mg
daily if the estimated glomerular filtration rate (eGFR) is 50 mL/
minute/1.73 m2 to 80 mL/minute/1.73 m2, 1500 mg if eGFR is 30 mL/
minute/1.73 m2 to 50 mL/minute/1.73 m2, and 1000 mg if eGFR is
less than 30 mL/minute/1.73 m2 (BNF 2019a). For children, dose is
reduced if the eGFR is less than 80 mL/minute/1.73 m2 (BNF 2019a).
Why it is important to do this review
It is important that estimates of the overall eGicacy, tolerability
and safety profiles of AEDs remain updated as new studies are
published. This is to help ensure clinicians and patients make
informed decisions on treatment using the most accurate and up-
to-date information available.
O B J E C T I V E S
To evaluate the eGectiveness of levetiracetam when used as an add-
on treatment for people with drug-resistant focal epilepsy.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Trials had to meet the following criteria.
• Randomised controlled trials (RCTs): included trials were
those for which the study author had described the trial as
'a randomised controlled trial' (or words to that eGect). A
judgement was then made on the risk of selection bias of
the included trials, based on the reported methods of random
list generation and allocation concealment (see Assessment of
risk of bias in included studies for details on which methods
conferred a low risk of selection bias).
• Placebo-controlled.
• Double, single, or unblinded: a judgement was then made on the
risk of performance and detection biases being present in the
trial (see Assessment of risk of bias in included studies).
• Parallel or cross-over design: for cross-over trials, the first
treatment period was treated as a parallel trial (i.e. only data
from the first treatment period were used).
• Consist of a treatment period of at least eight weeks in duration.
Types of participants
Participants had to meet all of the following criteria.
• Any age, gender, and ethnic background.
Levetiracetam add-on for drug-resistant focal epilepsy (Review)
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• Experiencing drug-resistant focal epilepsy: that is experiencing
focal seizures with or without impairment of consciousness
or awareness, with or without evolution to bilateral,
convulsive seizures (involving tonic, clonic, or tonic and clonic
components). There has been a lack of consensus between
studies when defining drug resistance (Mbizvo 2012). Therefore,
to allow a fair and inclusive evaluation of all trials that have
been said to involve drug-resistant participants, a specific cut-
oG for number of background AEDs and the time period on
these was not set. Instead, the requirement was for trials to have
described participants on AEDs as having 'failed to respond'
or having 'refractory', 'drug-resistant', or 'uncontrolled' epilepsy
(or words to that eGect). Information was then collected on
the duration of epilepsy, the number of AEDs tried, and the
length of time during which seizures had not responded to those
AEDs, and the minimum number of seizures required during
that time for participants to have been included in the trial.
Where relevant, a subgroup analysis was conducted to compare
primary outcomes between studies where the mean duration
of epilepsy was shorter (less than 12 months) and longer (12
months or greater).
Types of interventions
• The active treatment group received treatment with
levetiracetam in addition to conventional AED treatment.
• The control group received matched placebo in addition to
conventional AED treatment.
Types of outcome measures
Primary outcomes
1. 50% or greater reduction in focal seizure frequency
We chose the proportion of people with a 50% or greater reduction
in focal seizure frequency in the treatment period compared to
the prerandomisation baseline period as it is commonly reported
in this type of study, and can be calculated for studies that do
not report this outcome provided that baseline seizure data were
reported. For the purposes of this review, we termed people
who achieved 50% or greater reduction in focal seizure frequency
'responders'.
2. Treatment withdrawal
The proportion of people having treatment withdrawn during the
course of the treatment period was used as a measure of global
eGectiveness. Treatment is likely to be withdrawn due to adverse
eGects, lack of eGicacy, or a combination of both. It is also an
outcome to which the participants make a direct contribution. In
trials of short duration, it is likely that adverse eGects will be the
most common reason for withdrawal.
3. Adverse e7ects
3.1. Five most common adverse e7ects
The proportion of people experiencing the five most common
adverse eGects was reported.
3.2. General adverse e7ects
The proportion of people experiencing the following five adverse
eGects was also reported (where available and if diGerent from the






These adverse eGects were chosen as they were considered by the
review authors to be common and important adverse eGects of
AEDs generally.
3.3. Behavioural adverse e7ects
The proportion of people experiencing adverse eGects pertaining
to changes in behaviour (e.g. aggression, agitation, anger, anxiety,
apathy, depression, hostility, and irritability). Clinicians oQen
consider changes in behaviour to be common adverse eGects of
levetiracetam (Asconapé 2001; NICE 2012; Penovich 2004).
Secondary outcomes
1. Cognitive e7ects
At present, there is no consensus as to which instruments should
be used to assess the eGects of AEDs on cognition, and as a
result this has been approached in a heterogeneous way (Cochrane
1998). In view of this diGiculty, we intended to tabulate results
where a specific instrument had been used to assess the eGects of
levetiracetam on cognition, but made no attempt to combine the
results in a meta-analysis.
2. Quality of life
There is no consensus as to which instruments should be used
to assess quality of life (QoL), and QoL data were also tabulated
where a specific instrument had been used to assess the eGects of
levetiracetam on QoL. However, we made no attempt to combine
the results in a meta-analysis.
Search methods for identification of studies
Electronic searches
The first searches for the original review were in 2000. Subsequent
searches were in September 2002, July 2005, January 2010,
February 2011, April 2011, August 2012, March 2014, February
2015, March 2017, October 2017, and 26 November 2018. For the
latest update, we searched the following databases. There were no
language restrictions:
• Cochrane Register of Studies (CRS Web, 26 November 2018)
using the strategy set out in Appendix 1;
• MEDLINE (Ovid, 1946 to November 21, 2018) using the strategy
outlined in Appendix 2;
• ClinicalTrials.gov (26 November 2018) using the strategy
outlined in Appendix 3;
• WHO International Clinical Trials Registry Platform (ICTRP;
apps.who.int/trialsearch/; 26 November 2018) using the strategy
outlined in Appendix 4.
CRS Web includes the Cochrane Epilepsy Group Specialized
Register and the Cochrane Central Register of Controlled Trials
(CENTRAL).
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Searching other resources
References from published studies
We reviewed the reference lists of retrieved studies to search for
additional reports of relevant trials.
Other sources
We contacted colleagues in the field for information about any
unpublished or ongoing studies.
Data collection and analysis
Selection of studies
Two review authors (GKM and BC or PD) independently assessed
trials for inclusion. We first screened titles and abstracts, followed
by full-text reports of potentially eligible trials. A third review author
(AGM) resolved any disagreements.
Data extraction and management
Two review authors (GKM and BC or PD) extracted the information
shown below from included trials, with any disagreements
resolved by similar discussion. We contacted trial authors for
any information missing from the published manuscript that was
deemed relevant.
Publication details
• Year of trial publication.
Methodological/trial design
• Method of random sequence generation.
• Method of randomisation concealment (allocation
concealment).
• Method of blinding (of participants, personnel, and
investigators).
• Whether any randomised participants had been excluded from
reported analyses.
• Duration of baseline period.
• Duration of treatment period (uptitration and maintenance
phases).
• Dose(s) of levetiracetam tested.
Participant/demographic information
• Total number of participants allocated to each treatment group.
• Age and sex.
• Country or continents from which the majority of participants
had been recruited.
• Duration of epilepsy.
• Number with focal epilepsy.
• Seizure classification.
• Duration of time in which seizures were drug-resistant.
• Minimum seizure rate required for trial inclusion.
• Seizure frequency during the baseline period.
• Number of background AEDs.
Outcomes
• Number of participants experiencing each outcome (see Types
of outcome measures) was recorded per randomised group.
Assessment of risk of bias in included studies
Two review authors (GKM and PD or BC) independently assessed
trials for the risks of bias listed below (Higgins 2011). A third review
author (AGM) settled any disagreements. Where possible, we used
published data, and sought unpublished data when details were
unclear or unavailable.
• Selection bias: were there adequate methods of random
sequence generation and allocation concealment? Methods
considered to confer a low risk of selection bias included
those using random number tables/electronically generated
random numbers for random sequence generation, and those
using allocation of sequentially numbered sealed packages
of medication, sealed opaque envelopes, or central/telephone
randomisation for allocation concealment.
• Performance bias: was knowledge of the allocated
interventions by participants and personnel adequately
prevented during the study? Methods considered to confer a low
risk of performance bias included using packaging and tablets
that were identical for levetiracetam and placebo.
• Detection bias: was knowledge of the allocated interventions
by outcome assessors prevented during the study? Studies were
regarded at low risk of detection bias when it was specifically
described that investigators/outcome assessors were blinded to
treatment assignment.
• Attrition bias: were incomplete outcome data adequately
addressed? Reasons for low risks of this bias included no missing
outcome data, reasons for missing outcome data unlikely to
be related to true outcome, missing outcome data balanced in
numbers across intervention groups, with similar reasons for
missing data across groups, or for dichotomous outcome data,
the proportion of missing outcomes compared with observed
event risk not enough to have a clinically relevant impact on the
intervention eGect estimate.
• Reporting bias: were reports of the study free of suggestion of
selective outcome reporting? Risks were regarded as low when
the results of all outcomes measured (where the outcome was
also relevant to this review) were published.
In addition to providing overall estimates, a sensitivity analysis
that excluded trials with unclear or high risks of any of the biases
was performed for the primary outcome measure (50% or greater
reduction in seizure frequency).
Measures of treatment e7ect
For dichotomous outcomes, the preferred measure of treatment
eGect was the Mantel-Haenszel risk ratio (RR). We reported the
outcomes of 50% reduction in seizure frequency and treatment
withdrawal with 95% confidence intervals (CI). For individual
adverse eGects, we used 99% CI to make allowance for multiple
testing.
We summarised continuous outcomes (cognitive outcomes and
QoL) in tables and in the text rather than enter data into analysis
due to our perceived variability of how included studies would
assess these outcomes (see Secondary outcomes).
Unit of analysis issues
The unit of allocation and analysis was the participant for all
included trials.
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We considered a cross-over trial design as eligible for this review.
However, for such studies, we used the first treatment period as a
parallel trial (i.e. used only data from the first treatment period).
Dealing with missing data
All analyses included all participants in the treatment groups to
which they had been allocated (i.e. an intention-to-treat (ITT)
approach).
For the eGicacy outcome (50% or greater reduction in seizure
frequency), we undertook three analyses: primary ITT analysis,
worse-case analysis, and best-case analysis.
Primary intention-to-treat analysis
For this, all randomised participants were analysed in the
treatment group to which they had been allocated, irrespective of
the treatment that they actually received. Participants randomised
but excluded from analysis (e.g. for not completing follow-up or
with inadequate seizure data) were assumed non-responders.
Worse-case analysis
Participants randomised but excluded from analysis (e.g. for
not completing follow-up or with inadequate seizure data)
were assumed non-responders in the levetiracetam group and
responders in the placebo group.
Best-case analysis
Participants randomised but excluded from analysis (e.g. for
not completing follow-up or with inadequate seizure data)
were assumed responders in the levetiracetam group and non-
responders in the placebo group.
Assessment of heterogeneity
Statistical heterogeneity between trials was checked for each
outcome using a Chi2 test for heterogeneity and the I2 statistic,
interpreted as follows (Higgins 2011):
• 0% to 40%: heterogeneity levels might not be important;
• 30% to 60%: may represent moderate heterogeneity;
• 50% to 90%: may represent substantial heterogeneity;
• 75% to 100%: considerable heterogeneity.
The 2012 update already included regression modelling to assess
for trial factors that might explain significant levels of heterogeneity
(see Mbizvo 2012). This review update includes a random-
eGects model to report results where the levels of heterogeneity
were considered important (see Data synthesis). This review
also uses updated regression methods to augment the dose–
response analysis (see Subgroup analysis and investigation of
heterogeneity).
Assessment of reporting biases
To assess selective reporting bias, we assessed the consistency
of the measurements and outcomes planned by the original
investigators during the trial with those reported within the
published paper by comparing the trial protocols (when available)
with the information given in the final publication. Where protocols
were not available, we compared the 'Methods' and the 'Results'
sections of the published papers. We also used our knowledge of
the clinical background to identify standard outcome measures
usually taken but not reported by the trial investigators.
Where there were 10 or more studies for any comparison or
outcome, we investigated the presence of publication bias by
inspecting a funnel plot for asymmetry.
Data synthesis
We performed meta-analysis for all dichotomous outcomes using a
Mantel-Haenszel approach and an RR as the measure of treatment
eGect.
Provided there was no important heterogeneity (where important
heterogeneity was defined as P < 0.05 on Chi2 test, I2 > 50%,
or both), we used a fixed-eGect model for analysis. Where there
was important heterogeneity, we included a random-eGects model
to report results (see Subgroup analysis and investigation of
heterogeneity).
Subgroup analysis and investigation of heterogeneity
We assessed clinical and statistical heterogeneity using the
methods outlined in Assessment of heterogeneity. We conducted
subgroup analyses separating adult and paediatric trials. We
analysed dose–response for the outcomes 50% or greater reduction
in focal seizure frequency and treatment withdrawal. We evaluated
dose–response in trials with fixed doses (i.e. not doses based
on weight) using a generalised linear mixed model (i.e. a model
including both fixed and random eGects) with the logit link
function, as described in Turner 2000, and estimated using the
command xtmelogit in STATA SE version 14 (Stata). Study and
dose were included as fixed eGects within the mixed model while
treatment was included as a random-eGect within the mixed model
(no random-eGect was included for the constant term of the mixed
model). Dose was standardised to dose increases of 1000 mg. This
method estimated an odds ratio (OR) as opposed to an RR.
Sensitivity analysis
We performed a sensitivity analysis of the primary outcomes of the
review (where possible) based on the methodological quality of the
studies, restricting meta-analysis to only studies with a globally low
risk of bias.
Summary of findings and assessment of the certainty of the
evidence
We used the GRADE Working Group grades of evidence to
provide a 'Summary of findings' table outlining the overall
certainty of evidence, the magnitude of eGect of the interventions
examined, and the sum of available data on most important
outcomes (i.e. 50% or greater reduction in seizure frequency,
treatment withdrawal, and the five most common adverse eGects)
(Summary of findings 1; Schünemann 2009). Within this, 'assumed
risk' (also called baseline risk) was the control event rate and was
therefore a measure of the typical burden of these outcomes, and
'corresponding risk' was a measure of the burden of the outcomes
aQer the intervention was applied (i.e. the risk of an outcome in
levetiracetam-treated people based on the relative magnitude of
an eGect and assumed (baseline) risk). The GRADE system classifies
the certainty of evidence into one of four grades:
• high: further research is very unlikely to change our confidence
in the estimate of eGect;
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• moderate: further research is likely to have an important impact
on our confidence in the estimate of eGect and may change the
estimate;
• low: further research is very likely to have an important impact
on our confidence in the estimate of eGect and is likely to change
the estimate;
• very low: any estimate of eGect is very uncertain.
A judgement was made on the individual trials used to provide
the pooled eGect estimates and the certainty of evidence was then
downgraded by the presence of bias, inconsistency (heterogeneity),
indirectness, imprecision, and publication bias; and upgraded by
the presence of a large eGect and a dose–response gradient. Only
studies with no threats to validity (not downgraded for any reason)
can be upgraded.
Two review authors (GKM and SN) independently conducted this
process by with any disagreements resolved by discussion with a
third review author (AGM).
R E S U L T S
Description of studies
Results of the search
See Figure 1 for a flow-diagram summary of the results of database
searches and records identified from other sources. The previous
update of this review included 11 trials, and four potentially eligible
trials remained as awaiting classification pending receipt of further
information about the trials (Inoue 2015 (as N01221); Yagi 2010;
Zheng 2009; Boon 2002). Inoue 2015, Yagi 2010, and Zheng 2009
are now included in the current review following subsequent
receipt of further information. There was no further information for
Boon 2002, so this trial has been excluded. The search identified
NCT01392768 as an additional potentially eligible trial that awaits
classification pending receipt of further information from authors
(see Characteristics of studies awaiting classification).
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Figure 1.   Study flow diagram.
 
Included studies
See Characteristics of included studies table.
This update included 14 trials (2455 participants), seven of
which were published subsequent to the original 2001 review
(Glauser 2006; Levisohn 2009; Peltola 2009; Tsai 2006; Wu 2009;
Xiao 2009; Zhou 2008). The 2001 review analysed four included
studies using both published and unpublished trial information
and data (Ben-Menachem 2000; Betts 2000; Cereghino 2000;
Shorvon 2000). The unpublished information was obtained as
prepublished study protocols provided by UCB S.A. Pharma
sector. These study protocols were also available for use in
this current review, in addition to their corresponding published
manuscripts. The remaining trials were analysed using published
data only (prepublished study protocols were sought, where
relevant, but unobtainable). Data from Yagi 2010 and Zheng 2009
were successfully obtained subsequent to the 2012 review using a
translator.
Participants were 296 children in two trials (age range four to 16
years) (Glauser 2006; Levisohn 2009). The remaining trials included
2159 adults aged over 16 years. Aside from one cross-over trial
(Shorvon 2000), all trials were parallel design. Trials involving
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children (Glauser 2006; Levisohn 2009), and trials published earlier
(Ben-Menachem 2000; Betts 2000; Cereghino 2000; Shorvon 2000),
recruited from populations within various European countries
and the US. Adult trials published later largely recruited from
populations within Asian countries (mostly China and Taiwan)
(Inoue 2015; Tsai 2006; Wu 2009; Yagi 2010; Zheng 2009; Zhou 2008).
One trial recruited from various countries (centres in Finland, India,
Mexico, Russia, South Africa, and Ukraine) (Peltola 2009).
Three trials did not report the mean duration of epilepsy (Cereghino
2000; Levisohn 2009; Zheng 2009). For the Cereghino 2000 trial,
participants had to have experienced uncontrolled focal epilepsy
for at least two years, with a minimum of 12 focal seizures within
12 weeks before study selection and two focal seizures occurring
per four weeks during the 12-week baseline period. This was
on a background of at least two AEDs taken simultaneously or
consecutively. For the Levisohn 2009 trial, participants had to
have experienced uncontrolled focal epilepsy for a minimum of six
months, with a minimum of one focal seizure during the four weeks
prior to screening. This was on a background of one or two AEDs.
Across the remaining trials, the mean duration of epilepsy ranged
from seven to 26 years. Within these, the Betts 2000 trial required a
minimum of at least four seizures in the six months prior to study
entry. Three trials required at least two seizures per four weeks in
their 12-week (Ben-Menachem 2000; Inoue 2015), and their eight-
week (Peltola 2009), baseline periods. The Zheng 2009 trial required
eight seizures during the eight-week baseline period. Yagi 2010 did
not provide information regarding the number of seizures required
prior to study entry during the eight-week baseline period. The
remaining six trials required at least four seizures per four weeks
in their eight- or 12-week baseline periods (Glauser 2006; Shorvon
2000; Tsai 2006; Wu 2009; Xiao 2009; Zhou 2008). This was on a
background of one to four AEDs. The mean duration of epilepsy
across all included trials did not range below 12 months.
Treatment periods consisted of the combination of an uptitration
and a maintenance phase in all but two trials (Betts 2000 and
Peltola 2009 did not involve uptitration). Duration of the treatment
periods ranged from 12 to 24 weeks between trials (uptitration
range zero to four weeks, maintenance range eight to 24 weeks).
The doses of levetiracetam tested were 60 mg/kg/day for children,
and a range of 500 mg/day to 4000 mg/day for adults. The
Peltola 2009 trial was the only one that tested an extended-release
preparation of levetiracetam (1000 mg dose). The Inoue 2015 trial
was the only one that tested levetiracetam 500 mg. The Betts 2000
trial was the only one that tested levetiracetam 4000 mg. We were
able to calculate a 50% or greater reduction in seizure frequency
for all 14 trials. All trials provided data for treatment withdrawal,
while all but two trials (Zheng 2009; Zhou 2008), provided data for
adverse eGects. Generally, trials published an adverse eGect if 5% or
more of the participants in any treatment group were aGected, but
the Betts 2000 and Cereghino 2000 trials used a higher threshold of
10%.
Four trials provided data for cognitive eGects and QoL outcomes
in adults, but only 619/765 participants randomised to these trials
were assessed with the relevant instruments (Betts 2000; Cereghino
2000; Shorvon 2000; Zhou 2008). One trial provided outcome
data for cognitive as well as behavioural and emotional eGects
in children (Levisohn 2009). This trial assessed 73/99 participants
randomised with the relevant instruments. The three new trials
included in the current update did not contribute any data for the
cognitive eGects and QoL outcomes.
Overall, there was missing eGicacy outcome (50% or greater
reduction in seizure frequency) for 97 adults (70 randomised to
levetiracetam and 27 to placebo). These participants contributed to
the best- and worst-case scenario analyses.
Excluded studies
We excluded one trial from the review (Boon 2002). This was a cross-
over trial and data were not available from the first period to allow
this trial to be included in analyses.
Risk of bias in included studies
Figure 2 and Figure 3 summarise the risk of bias of the included
trials (see also Characteristics of included studies table).
 
Figure 2.   'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages
across all included studies (shown above).
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias): All outcomes
Blinding of outcome assessment (detection bias): All outcomes
Incomplete outcome data (attrition bias): All outcomes
Selective reporting (reporting bias)
0% 25% 50% 75% 100%
Low risk of bias Unclear risk of bias High risk of bias
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Ben-Menachem 2000 + + + + + +
Betts 2000 + + + + - -
Cereghino 2000 + + + + + +
Glauser 2006 + + + + - +
Inoue 2015 ? ? ? ? - +
Levisohn 2009 ? ? ? ? + +
Peltola 2009 + + + + + +
Shorvon 2000 + + + + + +
Tsai 2006 + + + + + +
Wu 2009 ? ? + ? + +
Xiao 2009 ? + + + + +
Yagi 2010 ? ? ? ? - ?
Zheng 2009 ? ? ? ? - +
Zhou 2008 + + ? ? - +
 
In summary, five RCTs were at overall low risk of bias (selection
bias, performance bias, detection bias, attrition bias, and reporting
bias; Ben-Menachem 2000; Cereghino 2000; Peltola 2009; Shorvon
2000; Tsai 2006). For the remaining RCTs, risks were largely unclear
although some risks of bias were high for the following trials: Betts
2000; Glauser 2006; Inoue 2015; Yagi 2010; Zheng 2009; Zhou 2008.
Allocation
Eight of the 14 trials described as RCTs provided details of
an adequate method of sequence generation and allocation
concealment to qualify them at low risk of selection bias (Ben-
Menachem 2000; Betts 2000; Cereghino 2000; Glauser 2006;
Peltola 2009; Shorvon 2000; Tsai 2006; Zhou 2008). Five trials
generated the random list using random permuted blocks, and
concealed allocation by dispensing sequentially numbered sealed
packages (Betts 2000; Cereghino 2000; Glauser 2006; Shorvon
Levetiracetam add-on for drug-resistant focal epilepsy (Review)









Cochrane Database of Systematic Reviews
2000; Tsai 2006). Ben-Menachem 2000 achieved randomisation
using a minimisation programme, which was concealed by using
telephone randomisation. Participants were randomised in a
2:1 ratio to levetiracetam or placebo. Peltola 2009 achieved
randomisation and allocation concealment using an interactive
voice response system. Participants were randomised in a 1:1
ratio to levetiracetam or placebo. Zhou 2008 used a random
numbers table for sequence generation, and participants received
an exclusive random number consecutively on entry into the trial,
with medication packaged by UCB S.A. Pharma.
The remaining six RCTs were at unclear risk of selection bias,
for which full details on the method of random list generation
or allocation concealment were not provided (Inoue 2015;
Levisohn 2009; Wu 2009; Xiao 2009; Yagi 2010; Zheng 2009).
The study sponsor generated randomisation codes for one
trial (no further specification given), with participants assigned
a randomisation number and given levetiracetam or placebo
accordingly (Xiao 2009). This trial described an adequate method
of allocation concealment (concealment via the use of numbered
containers). Wu 2009 and Levisohn 2009 provided no details
on the method of random sequence generation and allocation
concealment, although Levisohn 2009 reported that participants
were randomised in a 2:1 ratio to levetiracetam or placebo, and that
randomisation was stratified for age (four to seven years, eight to
12 years, 13 to 16 years) and number of concomitant AEDs (one or
two).
Blinding
All trials were described as double-blind. Nine trials provided
details that packaging and tablets were identical for levetiracetam
and placebo and were therefore at low risk of performance bias
(blinding of participants and personnel) (Ben-Menachem 2000;
Betts 2000; Cereghino 2000; Glauser 2006; Peltola 2009; Shorvon
2000; Tsai 2006; Wu 2009; Xiao 2009). The remaining five trials did
not describe the method used to blind participants and personnel,
and were at unclear risk of performance bias (Inoue 2015; Levisohn
2009; Yagi 2010; Zheng 2009; Zhou 2008). The risk of detection bias
was low in eight trials that reported that the investigators were
blinded to treatment assignment (Ben-Menachem 2000; Betts 2000;
Cereghino 2000; Glauser 2006; Peltola 2009; Shorvon 2000; Tsai
2006; Xiao 2009), and unclear in six trials that did not provide details
that the investigators were blinded to treatment assignment (Inoue
2015; Levisohn 2009; Wu 2009; Yagi 2010; Zheng 2009; Zhou 2008).
Incomplete outcome data
Eight trials were at low risk of attrition bias (Ben-Menachem 2000;
Cereghino 2000; Levisohn 2009; Peltola 2009; Shorvon 2000; Tsai
2006; Wu 2009; Xiao 2009). Six trials were at high risk, mainly owing
to discrepancies in the denominators compounded by reasons for
missing outcome data being potentially related to true outcome,
with either imbalance in numbers or reasons for missing data
across intervention groups (Betts 2000; Glauser 2006; Inoue 2015;
Yagi 2010; Zheng 2009; Zhou 2008, see Characteristics of included
studies).
Selective reporting
Twelve trials were at low risk of selective reporting bias (Ben-
Menachem 2000; Cereghino 2000; Glauser 2006; Inoue 2015;
Levisohn 2009; Peltola 2009; Shorvon 2000; Tsai 2006; Wu 2009;
Xiao 2009; Zheng 2009; Zhou 2008). Betts 2000 was at high risk as
there were no uniform baseline seizure data (see Characteristics of
included studies table). Yagi 2010 was at unclear risk.
E7ects of interventions
See: Summary of findings 1 Levetiracetam compared to placebo
for drug-resistant focal epilepsy




All trials (2455 participants) reported results for the 50% or greater
reduction in seizure frequency outcome. Considering all doses of
levetiracetam evaluated, more participants taking levetiracetam
compared to placebo achieved 50% or greater reduction in seizure
frequency (pooled RR 2.37, 95% CI 2.02 to 2.78; P < 0.00001;
moderate-certainty evidence; Analysis 1.1; Summary of findings
1). Ignoring dose, 36% of participants responded to levetiracetam
(95% CI 34% to 38%), with a placebo response of 17% (95% CI 15%
to 20%).
The Chi2 test for heterogeneity for response to levetiracetam
indicated an important level of statistical heterogeneity between
trials (Chi2 = 24.71, degrees of freedom (df) = 13 (P = 0.03)). This
signifies that there was a moderately large (I2 = 47%) amount of
variation (inconsistency) in the magnitude of the positive eGect of
levetiracetam overall. This is illustrated by the observations that
the proportion of adults responding to levetiracetam varied from
21% to 72%, with a median 42%, and the proportion of children
responding was 45% in one trial (Glauser 2006) and 63% in the
other trial (Levisohn 2009). Repeating all-dose analysis using a
random-eGects model, levetiracetam was still significantly better
than placebo (RR 2.26, 95% CI 1.79 to 2.85; P < 0.00001; Analysis 1.2).
There was no clear evidence of publication bias from inspecting
asymmetry of a funnel plot (Figure 4).
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Figure 4.   Funnel plot: 50% responder rate (fixed-e7ect analysis, based on Analysis 1.1).
 
Subgroup analysis: adult trials compared to paediatric trials
The above conclusions remained unchanged when analysis was
limited to the trials involving adults (all doses, pooled RR 2.49, 95%
CI 2.08 to 2.99; P < 0.00001; Analysis 1.3). Ignoring dose, 34% of
adults responded to levetiracetam (95% CI 32% to 37%), with a
placebo response of 16% (95% CI 13% to 18%). There remained
substantial heterogeneity within the trials involving adults (Chi2
= 21.83, df = 11 (P = 0.03); I2 = 50%). Repeating analysis using a
random-eGects model, levetiracetam was still significantly better
than placebo (RR 2.40, 95% CI 1.82 to 3.16; P < 0.00001; Analysis 1.4).
For the two trials that recruited children, the results were
suGiciently similar to be combined to give a pooled RR for 50% or
greater reduction in seizure frequency of 1.91 (95% CI 1.38 to 2.63;
P < 0.0001; Chi2 = 1.58, df = 1 (P = 0.21); I2 = 37%; Analysis 1.3). 52%
of children responded to levetiracetam (95% CI 44% to 59%), with
a placebo response of 25% (95% CI 18% to 34%). Overall, there was
no statistically significant diGerence in the results of trials recruiting
adults (all levetiracetam doses) and trials recruiting children (test
for subgroup diGerences: Chi2 = 2.01, df = 1 (P = 0.16); I2 = 50.3%;
Analysis 1.3).
Dose–response analysis
When considering individual doses, levetiracetam at either 500
mg or 4000 mg did not perform better than placebo for the 50%
or greater reduction in seizure frequency outcome (500 mg: RR
1.60, 95% CI 0.71 to 3.62; P = 0.26; 4000 mg: RR 1.64, 95% CI
0.59 to 4.57; P = 0.3; Analysis 1.1). Levetiracetam was significantly
better than placebo at all other individual doses (1000 mg to 3000
mg; Analysis 1.1). We fitted a generalised linear mixed model to
the data from Analysis 1.1 to estimate the eGect of dose on the
50% or greater reduction in seizure frequency outcome (details in
Data synthesis). The odds of response (50% reduction in seizure
frequency) were increased by nearly 40% (OR 1.39, 95% CI 1.23
to 1.58) with estimated between-study standard deviation of 0.49
(standard error (SE) 0.16)) for each 1000 mg increase in dose of
levetiracetam. In other words, this translates into an approximate
40% increase in the odds of response with an increase in dose from
1000 mg to 2000 mg of levetiracetam.
Handling missing data: best-case and worse-case scenarios
Conclusions remained mostly unchanged in best-case and worst-
case scenarios compared to the ITT approach (Analysis 1.5; Analysis
1.6). No outcome data was missing in the two trials recruiting
children, therefore results and conclusions were identical across all
scenarios. An important amount of heterogeneity was present in
many of the pooled dose analyses. Results were largely unchanged
when analysis was repeated using a random-eGects model for
the subgroups with large amounts of heterogeneity (Analysis 1.7;
Analysis 1.8).
Overall, the scenario analyses indicated that levetiracetam
continued to perform better than placebo for the 50% or greater
reduction in seizure frequency outcome even when missing data
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were taken into account. Significant levels of heterogeneity were
compounded by the missing data, meaning that the precise
magnitude of positive eGect remains unclear in the scenario
analyses.
Sensitivity analysis across trials with low risk of bias
When sensitivity analysis was conducted on the five trials
possessing a globally low risk of bias (Ben-Menachem 2000;
Cereghino 2000; Peltola 2009; Shorvon 2000; Tsai 2006), the above
conclusions were not changed for all three analyses (Analysis 1.9):
• ITT: pooled RR 2.93 (95% CI 2.25 to 3.81); P < 0.00001; Chi2 =
14.10, df = 4 (P = 0.007); I2 = 72%;
• best case: pooled RR 3.13 (95% CI 2.41 to 4.06); P < 0.00001; Chi2
= 12.54, df = 4 (P = 0.01); I2 = 68%;
• worst case: pooled RR 2.69 (95% CI 2.09 to 3.46); P < 0.00001; Chi2
= 14.54, df = 4 (P = 0.006); I2 = 72%.
Conclusions were also unchanged when sensitivity analysis was
repeated using a random-eGects model (Analysis 1.10).
Primary outcome: treatment withdrawal
Mantel-Haenszel meta-analysis
Intention-to-treat analysis
Thirteen trials (2428 participants) reported results for treatment
withdrawal (Ben-Menachem 2000; Betts 2000; Cereghino 2000;
Glauser 2006; Inoue 2015; Levisohn 2009; Peltola 2009; Shorvon
2000; Tsai 2006; Wu 2009; Xiao 2009; Yagi 2010; Zhou 2008).
Zheng 2009 reported that three participants withdrew from the
trial prematurely, one due to adverse reactions and two thought
'treatment was invalid' (translated into Engish from Zheng 2009
published in Chinese). However, it was not stated which treatment
groups these individuals withdrew from, therefore these data could
not contribute to analysis.
Considering all doses of levetiracetam evaluated, there was
no statistically significant diGerence between levetiracetam and
placebo in terms of participants withdrawing from treatment
(pooled RR 1.11, 95% CI 0.89 to 1.40; P = 0.36; high-certainty
evidence; Analysis 1.11).
A Chi2 test for heterogeneity for withdrawal from levetiracetam
treatment (all doses) indicated no important statistical
heterogeneity overall between trials (Chi2 = 12.00, df = 12 (P = 0.45);
I2 = 0%).
There was no clear evidence of publication bias from inspecting
asymmetry of a funnel plot (Figure 5).
 
Figure 5.   Funnel plot: treatment withdrawal (fixed-e7ect analysis, based on Analysis 1.11).
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Subgroup analysis: adult trials compared to paediatric trials
There were no statistically significant diGerences between any dose
of levetiracetam and placebo in terms of treatment withdrawal
(Analysis 1.11).
These conclusions also remained unchanged when analysis was
limited to trials involving children (pooled RR for treatment
withdrawal 0.80, 95% CI 0.43 to 1.46; P = 0.46; Chi2 = 3.04, df = 1, P =
0.08, I2 = 67%) and trials involving adults (pooled RR for treatment
withdrawal 1.18, 95% CI 0.92 to 1.51; P = 0.20; Chi2 = 7.90, df = 10 (P
= 0.64); I2 = 0%). Furthermore, there was no statistically significant
diGerence in the results for adults (all doses pooled) and children
(test for subgroup diGerences: Chi2 = 1.35, df = 1 (P = 0.24), I2 = 26.2%,
Analysis 1.12).
Conclusions for treatment withdrawal were unchanged when the
analysis was repeated using a random-eGects model for trials
recruiting children (Analysis 1.13).
Dose–response
We fitted a generalised linear mixed model to the data from Analysis
1.11 to estimate the eGect of dose on treatment withdrawal (details
in Data synthesis). There was no eGect of increasing dose on the
odds of withdrawal of treatment (OR 0.99, 95% CI 0.85 to 1.15, with
estimated between-study standard deviation of 0.59 (SE 0.20)) for
each 1000 mg increase in dose of levetiracetam).
Sensitivity analysis across trials with low risk of bias
When sensitivity analysis was conducted on the five trials
possessing a globally low risk of bias (Ben-Menachem 2000;
Cereghino 2000; Peltola 2009; Shorvon 2000; Tsai 2006), the above
conclusions were not changed (pooled RR for treatment withdrawal
1.26, 95% CI 0.90 to 1.76; Chi2 = 1.14, df = 4 (P = 0.89); I2 = 0%; Analysis
1.14).
Conclusions were also unchanged when sensitivity analysis was
repeated using a random-eGects model (Analysis 1.15).
Primary outcome: adverse e7ects
Five most common adverse e"ects
Thirteen trials (2425 participants) reported results for adverse
events (Ben-Menachem 2000; Betts 2000; Cereghino 2000; Glauser
2006; Inoue 2015; Levisohn 2009; Peltola 2009; Shorvon 2000; Tsai
2006; Wu 2009; Xiao 2009; Yagi 2010; Zhou 2008). Zheng 2009
reported that one participant withdrew from the trial due to an
adverse reaction but it was not stated which group this participant
was in and there was no further information regarding adverse
events. Therefore, Zheng 2009 was not included in analysis of
adverse events.
Not all trials reported the same adverse eGects, which altered
the denominators representing number of participants from which
RRs were calculated. To give a pooled summary of the five most
common adverse eGects across trials (2423 safety population),
trials where an adverse eGect was not reported (i.e. less than 5% or
10% of participants aGected: see Included studies) were assigned
zero events for that adverse eGect. With this analysis, the five most
common adverse eGects (at any age) were as follows (Analysis 1.16):
• somnolence: aGected 13% of participants (RR 1.62, 99% CI 1.19
to 2.20; P < 0.00001, I2 = 0%; moderate-certainty evidence);
• headache: aGected 8% of participants (RR 0.85, 99% CI 0.59 to
1.21; P = 0.23, I2 = 66%; low-certainty evidence);
• dizziness: aGected 7% of participants (RR 1.54, 99% CI 0.98 to
2.41; P = 0.01, I2 =15%; moderate-certainty evidence);
• fatigue (asthenia): aGected 6% of participants (RR 1.53, 99% CI
0.98 to 2.38; P = 0.01, I2 = 0%; moderate-certainty evidence);
• accidental injury: aGected 6% of participants (pooled RR 0.72,
99% CI 0.49 to 1.06; P = 0.03, I2 = 60%; low-certainty evidence).
Conclusions were also unchanged when analyses of headache
and accidental injury were repeated using a random-eGects model
(Analysis 1.17).
The relative commonality of individual adverse eGects did not
largely alter when analysis was limited to adults (Analysis 1.18),
aside from the introduction of infection (RR 1.76, 99% CI 1.03 to
3.02), which was more common than dizziness. Only the RRs for
somnolence (RR 1.57, 99% CI 1.13 to 2.20; P = 0.0005) and infection
were statistically significant with levetiracetam over placebo.
Accidental injury was statistically significantly more associated
with placebo than levetiracetam (RR 0.60, 99% CI 0.39 to 0.92; P =
0.002).
In children, somnolence remained the most common adverse
eGect, although it was not statistically significant over placebo
(RR 1.90, 99% CI 0.88 to 4.09; P = 0.03) and there was a wide CI
(Analysis 1.19). The next most common adverse eGects in children
were vomiting (RR 1.22, 99% CI 0.55 to 2.69; P = 0.52), pharyngitis
(RR 1.09, 99% CI 0.47 to 2.50; P = 0.79), aggression (hostility) (RR
1.72, 99% CI 0.64 to 4.63; P = 0.16), and accidental injury (RR 1.63,
99% CI 0.63 to 4.26; P = 0.19). These were no more common than in
placebo treatment.
In summary, somnolence was the only adverse eGect significantly
associated with levetiracetam compared to placebo overall.
General adverse e"ects
RRs for the general adverse eGects (where available) were: ataxia
(adults, unpublished data: 1.50, 99% CI 0.43 to 5.26; P = 0.40;
Analysis 1.18), nausea (adults: 1.37, 99% CI 0.47 to 4.00; P = 0.44;
Analysis 1.18), dizziness (children: 1.52, 99% CI 0.47 to 4.94; P = 0.36;
Analysis 1.19), and fatigue ((asthenia), children: 1.82, 99% CI 0.62 to
5.33; P = 0.15; Analysis 1.19).
There were no general adverse eGects significantly associated with
levetiracetam compared to placebo.
Behavioural adverse e"ects
There were no individual behavioural adverse eGects significantly
associated with levetiracetam compared to placebo.
Adverse eGects pertaining to changes in behaviour were described
as follows (see Analysis 1.20):
• hostility: aGected 0.98% of participants (RR 1.92, 99% CI 0.56 to
6.60; P = 0.17);
• personality disorder: aGected 0.82% (RR 1.10, 99% CI 0.30 to
3.95; P = 0.85);
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• nervousness: aGected 0.66% (RR 4.80, 99% CI 0.68 to 34.14; P =
0.04);
• depression: aGected 0.60% of participants (RR 1.41, 99% CI 0.25
to 7.85; P = 0.61);
• aggression: aGected 0.60% of participants (RR 1.42, 99% CI 0.27
to 7.42; P = 0.59);
• agitation: aGected 0.55% of participants (RR 6.17, 99% CI 0.66 to
57.79; P = 0.04);
• emotional lability: aGected 0.55% of participants (RR 1.44, 99%
CI 0.28 to 7.29; P = 0.56);
• psychomotor hyperactivity: aGected 0.49% of participants (RR
0.42, 99% CI 0.08 to 2.19; P = 0.18);
• irritability: aGected 0.27% of participants (RR 11.28, 99% CI 0.26
to 495.63; P = 0.10);
• abnormal behaviour: aGected 0.27% (RR 5.92, 99% CI 0.14 to
255.98; P = 0.22);
• altered mood: aGected 0.22% of participants (RR 4.85, 99% CI
0.11 to 216.99; P = 0.28);
• anxiety: aGected 0.22% of participants (RR 4.85, 99% CI 0.11 to
216.99; P = 0.28);
• dissociation: aGected 0.16% of participants (RR 0.14, 99% CI 0.00
to 6.77; P = 0.19).
When behavioural adverse eGects were combined, 4.53% of
participants were aGected (RR 1.87, 99% CI 1.19 to 2.95; P = 0.0004).
In this, 22.64% of children were aGected (RR 1.90, 99% CI 1.16 to
3.11; P = 0.0009) and 1.04% of adults were aGected (RR 1.79, 99% CI
0.59 to 5.41; P = 0.17).
Secondary outcome: cognitive e7ects
The additional trials included in this review update did not
contribute any data to cognitive eGects, meaning that there are no
new changes since the previous review for these outcomes.
See Table 1; Table 2; Table 3.
Table 1 shows results for Zhou 2008. This table shows mean
change from baseline for each treatment group, by way of variables
within a series of neuropsychological tests. The results indicate
that levetiracetam did not lessen/reduce cognitive function (no
worsening in variables was statistically significant). Performance
time on the Wisconsin Card Sorting Test (WCST) and Delayed
Logic Memory significantly improved for participants treated with
levetiracetam, but not for those treated with placebo.
Table 2 shows results for Levisohn 2009. This table shows mean
change from baseline for each treatment group, by scores within
the Leiter International Performance Scale-Revised Attention and
Memory (Leiter-R AM), Wide Range Assessment of Memory and
Learning-2 (WRAML-2), and Leiter International Performance Scale-
Revised, Examiner's Rating Scale (Leiter-R ERS) instruments. The
results indicate that levetiracetam did not lessen/reduce/impair
cognitive function in children; there were no significant changes in
either group of participants.
Table 3 shows more results for the Levisohn 2009 trial. This table
shows mean change from baseline for each treatment group, by
component of the Achenbach Child Behavior Checklist (CBCL)
and Child Health Questionnaire-Parent Form 50 (CHQ-PF50). The
results demonstrated statistically significant worsening of scores
in aggressive behaviour, externalising syndromes (consisting of
aggressive behaviour and rule-breaking behaviour), and total
problems in children treated with levetiracetam, but not those
treated with placebo.
Secondary outcome: quality of life
The additional trials included in this review update did not
contribute any data to QoL assessment, meaning that there are no
new changes since the previous review for these outcomes.
See Table 4; Table 5; Table 6; Table 7.
For adults, two trials used the Quality Of Life in Epilepsy Inventory
(QOLIE-31) as an instrument to measure QoL (Cereghino 2000; Zhou
2008), while two other trials used the Epilepsy Surgery Inventory
Scale (ESI-55) (Betts 2000; Shorvon 2000). One trial assessed
cognitive eGects using nine tests chosen from the Chinese version
of the Wechsler Adult Intelligence Scale-Revised (WAIS-RC) and
other tests commonly used to assess cognitive function (see Table
1) (Zhou 2008). For children, one trial assessed cognitive eGects
using the following series of instruments: Leiter-R AM, WRAML-2,
and Leiter-R ERS (Levisohn 2009). The same trial used the CBCL and
CHQ-PF50 to assess behavioural and emotional eGects.
Table 4 shows results for Cereghino 2000. This table shows
mean change from baseline for each treatment group, using the
subscale of QOLIE-31. Results indicate that compared to placebo,
participants treated with levetiracetam were significantly less
worried about seizures, and participants treated with levetiracetam
3000 mg had a significantly better overall QoL.
Table 5 shows results for Zhou 2008 using the QOLIE-31. They
indicate that compared to placebo, participants treated with
levetiracetam had significantly better cognitive functioning and
social function.
Table 6 shows results for Shorvon 2000. This table shows mean
change from baseline for each treatment group, by domain using
the ESI-55 scale. Results indicate that when compared to placebo,
participants treated with levetiracetam scored significantly better
for the health perception domain. Participants treated with 1000
mg scored significantly better for the 'role limitation due to
memory problems', 'pain', 'energy', 'social functioning', and 'role
limitation due to physical problems' domains. Individuals treated
with levetiracetam 2000 mg scored better but not statistically
significantly for the overall QoL domain.
Table 7 shows results for Betts 2000 using the ESI-55; however, for
this trial we only had aggregate data for the three composite scores
of this instrument.
Overall, for adults, results from the Cereghino 2000, Shorvon 2000,
and Zhou 2008 trials did indicate that levetiracetam had a positive
eGect on some aspects of QoL, while results from the Zhou 2008
trial indicated that the drug did not negatively aGect and, in a
way, improved cognitive function. In children, the results from
the Levisohn 2009 trial indicated that levetiracetam did not alter
cognitive function but did worsen aspects of child behaviour.
D I S C U S S I O N
Summary of main results
Overall, this review update found that in both adults and children
with drug-resistant focal epilepsy, levetiracetam added on to usual
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care is more eGective than placebo at reducing seizure frequency,
it is unlikely to be stopped by patients, and it has minimal adverse
eGects. These findings are unchanged from the previous review
update in 2012 (Mbizvo 2012).
This review update contributes two key additional findings:
• a 500 mg daily dose of levetiracetam is no more eGective than
placebo at reducing seizures; and
• the odds of response (50% reduction in seizure frequency) are
increased by nearly 40% for each 1000 mg increase in dose of
levetiracetam.
In adults, levetiracetam demonstrated statistically significant
eGicacy over placebo in the outcome 50% or greater reduction
in seizure frequency at all doses aside from 500 mg and 4000
mg. Inoue 2015 contributed data to suggest levetiracetam 500 mg
lacked eGicacy. As this result was only provided by one study,
which had a high risk of bias from incomplete outcome data (see
Characteristics of included studies), this finding remains to be
confirmed in future RCTs. However, if correct, this finding would
have important implications given that it is not uncommon, in
clinical practice, for patients treated with levetiracetam to remain
on a low dose of 250 mg twice daily for prolonged periods of time.
It would suggest that there should be a low threshold to escalate
the dose beyond 500 mg if well-tolerated and eGicacy aims to be
achieved. Betts 2000 contributed data to suggest levetiracetam
4000 mg lacked eGicacy. This trial was excluded from the 50%
or greater reduction in seizure frequency outcome in both the
2001 (Chaisewikul 2001) and 2012 (Mbizvo 2012) reviews because
uniform baseline seizure data were not collected for the trial's
participants (see Characteristics of included studies). However,
in order to maximise information gathered within the context of
few new additional trials published since the 2012 update, we
decided to include the Betts 2000 data in the 50% or greater
reduction in seizure frequency outcome but also to grade the trial
as possessing high risks of bias from incomplete outcome data
and selective reporting (see Risk of bias in included studies). The
finding that 4000 mg daily of levetiracetam is no more eGective
than placebo should, therefore, be interpreted with caution and
would require confirmation in future RCTs if safe, although we
cannot recommend this as the maximum recommended dose of
levetiracetam is 3000 mg daily (BNF 2019a). We were able to
demonstrate a dose–response relationship for levetiracetam in the
order of 40% improvement in response for each 1000 mg increase in
dose for adults. This helps supplement previous focused studies on
the dose–response of levetiracetam in drug-resistant focal epilepsy,
which managed to use only some of the trials included in the
current review update (Snoeck 2007).
For our global outcome of treatment withdrawal, we have
insuGicient evidence to conclude that levetiracetam is more
likely to be withdrawn than placebo in adults. Somnolence and
infection were the only adverse eGects significantly associated
with levetiracetam in adults. Somnolence is a common complaint
among people with epilepsy because AEDs and seizures can modify
sleep architecture and thereby lead to daytime sleepiness (Manni
2000). It remains possible, therefore, that significant somnolence
was a general function of taking an AED rather than a specific
marker of levetiracetam. We are unable to explain the apparent
correlation between infection and levetiracetam. This adverse
eGect was apparent in the 2012 review and the three additional
studies reported in the current review did not report this adverse
eGect, meaning no new conclusions are drawn but we note that
the CI is wide (99% CI 1.03 to 3.02). This outcome requires
further investigation, particularly given that practicing clinicians
would not commonly associate levetiracetam with infection. The
lack of evidence of treatment withdrawal on levetiracetam would
favour that the adverse eGects profile of levetiracetam was
generally tolerable. Of note, there remained no significant evidence
to suggest that behavioural adverse eGects were significantly
associated with levetiracetam in adults, both individually or as
grouped behavioural adverse eGects.
There were only two paediatric trials in the 2012 update (Glauser
2006; Levisohn 2009), and the current review identified no more
RCTs of levetiracetam published since then for children with
drug-resistant focal epilepsy. The conclusions for children remain
unchanged: levetiracetam, at a dose of 60 mg/kg/day, is more
eGective than placebo at achieving response (50% or greater
reduction in seizure frequency), with an RR of 1.91 in favour of
levetiracetam. It is also no more likely to be withdrawn by children
than placebo. There are no individual adverse eGects significantly
associated with levetiracetam as compared to placebo in children.
However, our focused review of behavioural adverse eGects (as
a group) suggests that children may be significantly aGected by
these.
Children remained better responders than adults, with 52% of
children responding to levetiracetam compared to 34% of adults.
Placebo response was 25% for children and 16% for adults, making
the absolute response (levetiracetam minus placebo) 27% for
children and 18% for adults. The expected placebo response in
drug-resistant focal epilepsy is 9.3% to 16.6% (Burneo 2002; Guekht
2010). The reasons for larger placebo responses than expected in
the current pool of trials are unclear and merit further investigation.
However, such a large response to placebo, when taken in the
context of levetiracetam demonstrating a significant eGect in
reducing seizures over placebo, suggests that levetiracetam is a
highly eGective AED. There were no substantive diGerences in
results between the ITT analysis and the sensitivity best-case and
worst-case analyses for either adults or children.
As was the case in 2012 (Mbizvo 2012), we have insuGicient data
and analysis to make firm conclusions about the cognitive eGects
of levetiracetam and its eGect on QoL. Levetiracetam appeared to
have a positive eGect on cognition and some aspects of QoL in
adults. In children, levetiracetam did not appear to alter cognitive
function but there was evidence of worsening in certain aspects of
child behaviour. The three additional trials included in this update
reported no data on these outcomes. We made no attempt at a
meta-analysis across data pertaining to cognitive eGects and QoL.
It is diGicult to be sure of the real-life impact of any changes in
cognitive eGects or QoL seen in this analysis and the conclusions
remain to be validated in a more detailed investigation on the
eGects of levetiracetam on cognition and QoL. These outcomes
are important because they can place clinical trial evidence of
clinical eGicacy into the context of meaningful life improvement for
patients (Kerr 2011).
Overall completeness and applicability of evidence
The review sought out to evaluate the eGectiveness of
levetiracetam, added on to usual care, in treating drug-resistant
focal epilepsy. The evidence analysed is highly relevant to the
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review aims as all RCTs aimed to answer this same question, and
pooled results covered adults and children, and a range of low-,
middle-, and high-income countries. This is likely to mean that
the results of this review are generalisable, with suGicient external
validity to suggest levetiracetam is likely to have similar eGects
in drug-resistant focal epilepsy populations worldwide. However,
the trials analysed in this review treated people with levetiracetam
for only 12 to 24 weeks. People with drug-resistant focal epilepsy
need longer-term treatment than this, yet the conclusions drawn
in the current review cannot be applied to periods outside of
12 to 24 weeks of treatment. The conclusions on children are
also based on a sample size of fewer than 300 participants. More
studies, particularly longer-term studies, and studies on children
will be needed before complete evaluation of the eGectiveness of
levetiracetam is possible.
Although the results of this review indicate that levetiracetam is
an eGective add-on treatment for both adults and children with
drug-resistant focal epilepsy, it cannot tell us how levetiracetam
compares with other AEDs in this scenario. This is an extremely
important issue for clinicians who are faced with an ever-increasing
number of AEDs to choose from, and head-to-head trials are
needed to provide the evidence that is needed to enable clinicians
to make an evidence-based choice between AEDs. This review
focuses on the use of oral levetiracetam in drug-resistant focal
epilepsy, and the results cannot be generalised to add-on treatment
in people with generalised epilepsy. Likewise, no inference can be
made about the eGicacy and tolerability of levetiracetam when
used as monotherapy or as an intravenous agent.
Certainty of the evidence
The overall certainty of evidence for the response outcome (50%
or greater reduction in seizure frequency, all doses) was moderate
(see Summary of findings 1), indicating that further research is
likely to have an important impact on our confidence in the
estimate of eGect and may change the estimate. This certainty
score was downgraded from high due to the presence of important
levels of heterogeneity between trials, and due to high or unclear
risks of bias being present in 9/14 studies. Although levetiracetam
significantly outperformed placebo for the response outcome,
the heterogeneity meant we could not be confident about the
magnitude of this eGect. The strong performance of levetiracetam
in this regard, and its already widespread clinical use for this group
of patients, means that there are unlikely to be many future RCTs
set up to investigate levetiracetam in this particular population.
Therefore, the certainty of evidence for this particular outcome
is unlikely to improve in the future. We performed a sensitivity
analysis restricting analysis to studies with a low risk of bias (which
would act to increase the certainty of evidence). This subgroup
analysis did not change the results from the main analysis,
suggesting that any downgrade in the certainty of evidence owing
to bias would not significantly change our confidence in the primary
conclusions drawn.
The overall certainty of evidence for the treatment withdrawal
outcome was high (see Summary of findings 1), indicating that
further research is very unlikely to change our confidence in this
estimate of eGect.
The overall certainty of evidence for the adverse eGects of
somnolence, dizziness, and fatigue was moderate (see Summary of
findings 1). This was downgraded from high due the presence of
high or unclear risks of bias in many of the corresponding trials. For
headache and accidental injury, the overall certainty of evidence
was low because of the presence of high or unclear risks of bias and
due to heterogeneity between the corresponding trials. A grading
of low indicates that further research is very likely to have an
important impact on our confidence in the estimate of eGect and is
likely to change these estimates. This remains to be investigated.
Potential biases in the review process
The influence of a possible information bias cannot be excluded
in this review. The original review had unpublished data
confidentially made available for inclusion (Chaisewikul 2001),
while this update had no such data made available for the trials
published since the original review. To illustrate this limitation, the
risks of selection, performance, and detection biases were initially
regarded as 'unclear' for the Ben-Menachem 2000 and Shorvon
2000 trials (included in the original review). This judgement was
made based on the information available in the published versions
of these trials. These trials were regarded as possessing a 'low
risk' of these biases only aQer we had the opportunity to extract
further information from the unpublished scripts. It stands to
reason that similar discrepancies in information may exist for
the other trials regarded as having an 'unclear risk' of certain
biases in this review. Most RCTs implement various adequate
methods of random sequence generation, allocation concealment,
and investigator blinding in their protocols, but not all publish
details about these methods. Future trial publications should aim
to reduce this discrepancy in information in order to allow a clearer
interpretation of the risks of bias. The influence of this possible
information bias on the conclusions of this review is likely to be
small given that a predominant number of trials had low risks of
bias and a subgroup analysis where trials with unclear or high
risks of bias were excluded demonstrated negligible changes to the
results. Funnel plots suggest that there is unlikely to be existent
publication bias in the literature surrounding the subject of this
review (Figure 4; Figure 5).
Agreements and disagreements with other studies or
reviews
A meta-analysis of levetiracetam for randomised placebo-
controlled trials in people with refractory epilepsy was published
in April 2019 by a group in China (Chen 2019). Although this pooled
together results for both focal and generalised epilepsies across 17
trials, 15 trials were in focal epilepsy. We captured all 15 of these
same trials in the current review, and aQer choosing to exclude the
Boon 2002 trial (see Excluded studies), we included 14 of them. The
Chen 2019 review concluded that levetiracetam is an eGective AED
for both adults and children with generalised or focal seizures at
1000 mg to 3000 mg or 60 mg/kg/day, with a favourable adverse
eGects profile. These conclusions echo those of our own within the
current review. The agreement of these two reviews on eGicacy
and tolerability of levetiracetam in focal epilepsy is reassuring. The
observation that these two unrelated reviews identified the same
trials is also reassuring for quality and completeness of the search
methodology and study screening protocols used.
In the current review, behavioural adverse eGects, when looked at
individually, were not significant in adults or children. Similarly,
they were not significant in adults alone. However, when individual
behavioural adverse eGects were pooled, they became significantly
associated with levetiracetam over placebo in children (but not
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adults). This requires further investigation, as highlighted in more
detail in the Mbizvo 2012 update. A systematic review published
following that update reported an RR of 2.18 for the total number
of behavioural adverse eGects for levetiracetam versus placebo in
children (Halma 2014). However, in addition to the Glauser 2006
and Levisohn 2009 trials, that systematic review included one
RCT of children with generalised epilepsies in the analysis pool.
The paucity of further RCTs in children with drug-resistant focal
epilepsy make it diGicult for further conclusions to be drawn about
behavioural adverse eGects in this particular group of children with
epilepsy. For both adults and children, it is generally felt, in clinical
practice, that changes in behaviour are common when taking
levetiracetam. This is resultant from clinical experience although
the RCTs do not demonstrate clear evidence for this, as we have
demonstrated in the current review. One of the reasons for this
discrepancy may be the exclusion, in RCTs, of participants with
psychiatric comorbidities (whom clinicians would see routinely).
Of note, in one observational study on the adverse eGects of 4085
adults treated with AEDs, levetiracetam had the greatest rate of
psychiatric and behavioural side eGects (PBSE). Furthermore, a
history of psychiatric comorbidity was, indeed, one of the risk
factors for increased PBSE rate (Chen 2017). It may also be that
changes in behaviour manifest soon aQer starting levetiracetam,
meaning that it is withdrawn before the eight-week minimum
treatment period that was set for included trials in this review.
Finally, we note that only one of the four early trials from the year
2000 reported behavioural adverse eGects (depression in Shorvon
2000). It is possible that the questions or instruments used to
pick up adverse eGects in RCTs, particularly early ones, were not
sensitive for changes in behaviour because these were not the sort
of adverse eGect expected of an AED.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
This review provides moderate- to high-certainty evidence that
levetiracetam is eGective as add-on treatment in adults and
children with drug-resistant focal epilepsy, although an aGective
dose is likely to be above 500 mg daily in adults. The maximum
eGective dose remains unclear, with a suggestion that 4000
mg may not be eGective for this particular group of patients.
However, this is based on one study with high risk of bias and
therefore poor-quality evidence, meaning that this finding should
be interpreted with caution and may not be certain. As the
maximum recommended dose of levetiracetam is 3000 mg daily
(BNF 2019a), further comment on the implications for clinical
practice of levetiracetam 4000 mg is beyond the scope of this
review. The review demonstrates that nearly 30% of children may
be responsive to adjuvant levetiracetam at a dose of 60 mg/kg/day.
EGicacy also remains high in adults, with nearly 20% responding.
Each increase of dose by 1000 mg may provide a 40% increase in the
odds of achieving response (50% reduction in seizure frequency)
in adults. Low- to moderate-certainty evidence provided by this
review suggests that all doses appear well tolerated in both adults
and children, although there is a possibility of adverse changes in
behaviour in children, potentially aGecting around 20%. Overall, it
appears reasonable to continue the use of adjuvant levetiracetam
in clinical practice for treating adults and children with drug-
resistant focal epilepsy. The conclusions cannot be applied to
levetiracetam use in generalised epilepsy, as an intravenous agent,
or to its use as monotherapy.
Implications for research
To evaluate further the place of add-on levetiracetam in drug-
resistant focal epilepsy, further studies are required to address the
following:
• the eGicacy of a 500 mg daily dose of levetiracetam;
• the minimum and maximum eGective and safe doses of
levetiracetam;
• the most eGective dose of levetiracetam;
• the long-term eGicacy and safety of levetiracetam beyond 24
weeks;
• the eGects of levetiracetam on behaviour;
• the eGects of levetiracetam on quality of life and cognition;
• economic aspects of levetiracetam therapy;
• how levetiracetam compares with other add-on treatments;
• placebo response in randomised controlled trials of
levetiracetam;
• the eGectiveness of levetiracetam in children (using larger
sample sizes to supplement the currently small body of
evidence).
Beyond this group of patients, further investigation will also
be needed on how levetiracetam compares with standard AEDs
such as: 1. carbamazepine as monotherapy in focal epilepsy, 2.
lamotrigine as monotherapy in focal epilepsy, and 3. valproate
as monotherapy in generalised epilepsy. The eGectiveness of
levetiracetam versus standard AEDs will be studied in the SANAD-
II trial.
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Characteristics of included studies [ordered by study ID]
 
Study characteristics
Methods Randomised, double-blind, PCB-controlled, parallel trial
Multicentre across Europe
2 treatment arms: 1 LEV; 1 PCB
Randomisation concealment: telephone randomisation. Random list generation: centralised minimisa-
tion procedure of an unbalanced randomisation list (2 LEV:1 PCB)
Blinding: identical tablets and packages. Investigators were described as blinded to treatment assign-
ment. If treatment code was broken, the participant had to be removed from the trial
Ben-Menachem 2000 
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Baseline: 12 weeks. Treatment period: 16 weeks (4 weeks' titration, 12 weeks' maintenance)
Participants All adults
Total randomised 286 adults; all with drug-resistant focal epilepsy
181 adults to LEV 3000 mg; 105 adults to PCB
48% male
Age range: 17–70 years
Other AEDs: 1
≥ 2 focal seizures per 4 weeks during 12-week baseline
≥ 1-year history of focal epilepsy
Mean duration of epilepsy(years): LEV: 19 (SD 11); PCB: 19 (SD 12); overall: 19 (SD 11)
Median baseline seizure frequency per week: 1.7; range: 0.3–1.7
Interventions LEV 3000 mg/day
PCB
Uptitration dosages: titrated upwards every 2 weeks from 500 mg twice daily to the target dosage of
1500 mg twice daily
Outcomes ≥ 50% reduction in seizure frequency
Treatment withdrawal
Adverse effects
Notes 10 participants randomised to levetiracetam were not analysed, with reasons given. Three participants
randomised to placebo were not analysed, with reasons also given. These participants contributed to
our best-case and worst-case sensitivity analyses. In this iteration, we used the published outcome da-
ta on 50% or greater reduction in seizure frequency for this trial, having previously used the data ob-
tained in the unpublished trial manuscripts in 2012.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)




Low risk Investigator confirmed the participants' eligibility, then called the central ran-





Low risk Identical LEV and PCB tablets and packaging.
Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk Investigators described as blinded.
Incomplete outcome data
(attrition bias)
Low risk All participants who were randomised were analysed in the groups they were
initially assigned to notwithstanding premature terminations. The reasons or
Ben-Menachem 2000  (Continued)
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All outcomes outcomes (or both) for premature terminations were stated. There were suffi-
cient data to allow an ITT as well as best-case and worst-case sensitivity analy-
ses to be conducted where required.
Selective reporting (re-
porting bias)






Methods Randomised, double-blind, PCB-controlled, parallel trial
Multicentre across Europe
3 treatment arms: 2 LEV and 1 PCB
Randomisation concealment: allocated sequentially sealed, numbered packages containing either LEV
or PCB. Random list generation: computer-generated random permuted blocks (size 3).
Blinding: identical tablets and packages. Investigators were described as blinded to treatment assign-
ment. If treatment code was broken, the participant had to be removed from the trial.
Baseline: 4 weeks. No titration period. Treatment period: 24 weeks
Participants All adults
Total randomised 119 adults
42 adults to LEV 2000 mg; 38 adults to LEV 4000 mg; 39 adults to PCB
61% male
Age range: 16–67 years
Other AEDs: 1–3
≥ 4 seizures in 6 months before study entry
Mean duration of epilepsy (years): LEV 2000 mg: 21.1 (SD 14.4); LEV 4000 mg: 24.6 (SD 15.6); PCB: 26.0
(SD 13.2)
Median of baseline seizure frequency per week: LEV 2000 mg: 1.21; LEV 4000 mg: 1.34; PCB: 1.24





QoL and cognitive effects
Notes Baseline seizure frequency data were derived from 34 participants in LEV 2000 mg group, 36 partici-
pants in LEV 4000 mg group; 36 participants in PCB group
In the text for the trial, the number of participants in the inferential ITT population was reported as 27
for LEV 2000 mg, 28 for LEV 4000 mg, and 31 for PCB groups. In a graph for the trial, the number of par-
Betts 2000 
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ticipants in the inferential ITT population was reported as 26 in LEV 2000 mg, 28 in LEV 4000 mg, and
25 in PCB groups. The number of participants forming the denominator changed without account be-
ing provided by the authors on the reasons for this or the participants' response to treatment, resulting
in high risk of bias gradings for incomplete outcome data and selective reporting. The missing partici-
pants contribute to our best-case and worst-case analyses.
All participants had drug-resistant epilepsy and some had generalised-onset and unclassified seizures.
QoL was assessed using the ESI-55 for 30 or 31 participants in LEV 2000 mg, 26–28 participants in LEV
4000 mg, and 28 participants in PCB groups.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Blocked (restricted) randomisation generated by the RANUNI function of SAS
software performed the permutation of the 3 treatment numbers.
Allocation concealment
(selection bias)
Low risk Treatment group allocated according to which country the study took place,





Low risk 500 mg tablet for LEV and PCB. Identical in taste and appearance. Provided by
UCB S.A. Pharma. Participants withdrawn if the double-blind code was broken.
Blinding of outcome as-
sessment (detection bias)
All outcomes




High risk Baseline seizure frequency data were derived from 34 participants in the LEV
2000 mg, 36 in the LEV 4000 mg, and 36 in the PCB groups. In the text for the
trial, the number of participants in the inferential ITT population was reported
as 27 in the LEV 2000 mg, 28 in the LEV 4000 mg, and 31 in the PCB groups. In a
graph for the trial, the number of participants in the inferential ITT population
was reported as 26 in the LEV 2000 mg, 28 in the LEV 4000 mg, and 25 in the
PCB groups. The number of participants forming the denominator changed
without account being provided by the authors on the reasons for this or the
participants' response to treatment.
Selective reporting (re-
porting bias)





Methods Randomised, double-blind, PCB-controlled, parallel trial
Multicentre across USA
3 treatment arms: 2 LEV and 1 PCB
Randomisation concealment: allocated sequentially sealed, numbered packages containing either LEV
or PCB. Random list generation: random permuted blocks
Blinding: identical tablets and packages. Investigators were described as blinded to treatment assign-
ment. If treatment code was broken, the participant had to be removed from the trial.
Cereghino 2000 
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Baseline: 12 weeks. Treatment period: 18 weeks (4 weeks' titration, 14 weeks' maintenance)
Participants All adults
Total randomised 294 adults
98 adults to LEV 1000 mg; 101 adults to LEV 3000 mg; 95 adults to PCB
61% men
Age range: 16–70 years
Other AEDs ≥ 1
≥ 2 focal seizures per 4 weeks during 12-week baseline
≥ 2-year history of uncontrolled focal epilepsy
Mean duration of epilepsy (years): not given
Median baseline seizure frequency per week: 2.13; range: 0.15–163.56
Interventions LEV 1000 mg/day
LEV 3000 mg/day
PCB add-on
Uptitration dosages = LEV dose was escalated at 2-week intervals during the titration period. Doses of
LEV were 333 mg/day for 2 weeks, then 666 mg/day for 2 weeks, and 1000 mg/day started on the first
visit of the observation period, or 1000 mg/day, 2000 mg/day, then 3000 mg/day.
Outcomes ≥ 50% reduction in seizure frequency
Treatment withdrawal
Adverse effects
QoL and cognitive effects
Notes A minority of participants also had generalised or unclassified seizures, or both, in addition to par-
tial-onset seizures.
1 participant in LEV 1000 mg was excluded from 50% responder analysis.
QoL assessed using the QOLIE-31 for 80 participants in LEV 1000 mg, 85 participants in LEV 3000 mg,
and 81 participants in PCB.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation was in blocks by study site. Each participant was assigned a




Low risk The treatment identity (LEV/PCB) and dosage (1000 mg/day or 3000 mg/day)
for each participant were contained in sealed envelopes label with the trial




Low risk All study medication was blinded. The PCB and all strengths of LEV were iden-
tical in appearance, shape, size, colour, and smell. Unbroken tablets were
equal in taste.
Cereghino 2000  (Continued)
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All outcomes
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk All participants who were randomised (294) were analysed in the groups
they were initially assigned. They were included in the analysis regardless of
whether they finished the trial. The numbers randomised in each arm were 95
adults to LEV 1000 mg/day, 101 adults to LEV 3000 mg/day, and 95 adults to
PBC.
There was sufficient data to allow an ITT, as well as best-case and worst-case
sensitivity analysis to be conducted.
Selective reporting (re-
porting bias)






Methods Randomised, double-blind, PCB-controlled trial
Multicentre (60 centres) across the US and Canada
2 treatment arms: 1 LEV and 1 PCB
Randomisation concealment: randomisation schedule was performed by centre and participants were
allocated sequentially. Random list generation: computer-generated schedule with a permuted block
(size 4).
Blinding: identical tablets and packages. Investigators, site personnel, study personnel from the con-
tract research organisation responsible for the monitoring and conduct of the trial, and study sponsor
personnel were described as blinded to treatment assignment.
Baseline: 8 weeks. Treatment period: 14 weeks (4 weeks' titration, 10 weeks' maintenance)
Participants All children
Total randomised 216 children; all with drug-resistant focal epilepsy
101 children to LEV 60 mg/kg/day and 97 children to PCB
54% boys in LEV; 47% boys in PCB
Age range: 3–17 years
Other AEDs 1 or 2
≥ 4 focal seizures per 4 weeks during 8-week baseline
≥ 4 focal seizures during 4 weeks before screening
Diagnosis of uncontrolled focal epilepsy made ≥ 6 months before screening
Mean duration of epilepsy (years): LEV: 7.4; PCB: 6.8
Median baseline seizure frequency per week: LEV: 4.7 (range 0–696); PCB: 5.3 (range 0–467)
Interventions LEV 60 mg/kg/day
Glauser 2006 
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PCB add-on
Uptitration dosages 20 mg/kg/day, increasing every 2 weeks
Outcomes ≥ 50% reduction in seizure frequency
Treatment withdrawal
Adverse effects
Notes Before breaking the blinding, 18 participants were excluded, including all 16 participants at 1 site who
were excluded because of extensive violation of the protocol and consequent unreliability of the da-
ta, and 2 participants because they discontinued before taking any study medication. It was unclear to
which groups the 16 participants were assigned.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation was in blocks by study site. Each participant was assigned a




Low risk The treatment identity (LEV/PCB) and dosage (LEV1000 mg/day or 3000 mg/
day) for each participant were contained in sealed envelopes labelled with the





Low risk All study medication was blinded. The PCB and both strengths of LEV were
identical in appearance, shape, size, colour, and smell. Unbroken tablets were
equal in taste.
Blinding of outcome as-
sessment (detection bias)
All outcomes




High risk Although reported as an ITT analysis, before breaking the blinding, 18 ran-
domised participants were excluded, including all 16 participants at 1 site who
were excluded because of extensive violation of the protocol and consequent
unreliability of the data, and 2 participants because they discontinued be-
fore taking any study medication. It was unclear to which groups the 16 par-
ticipants were assigned or what their outcomes were. Therefore, the reason
for missing outcome data could be related to true outcome, with either im-
balance in numbers or reasons for missing data across intervention groups.
In a study of this size, the proportion of missing outcomes compared with ob-










Methods Randomised, double-blind, PCB-controlled, parallel trial
Multicentre, across Japan
Inoue 2015 
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5 treatment arms: 4 LEV and 1 PCB
Randomisation concealment: method not specified. Random list generation: method not specified.
Blinding: study described as double blind. Method not specified.
Baseline: 12 weeks. Treatment period: 16 weeks (4 weeks' titration, 12 weeks' maintenance). Followed
by 4 weeks' downtitration or transition period.
Participants All adults
Total randomised 352 adults; 351 analysed (1 excluded due to drug dispensing error)
71 adults to LEV 500 mg; 70 adults to LEV 1000 mg; 70 adults to LEV 2000 mg; 70 adults to LEV 3000 mg;
70 adults to PCB
54% men in LEV; 47% men in PCB
Age range: 16–64 years
Other AEDs: 1–3
≥ 12 focal seizures during 12-week baseline, ≥ 2 every 4 weeks
History of partial seizure > 2 years, with EEG confirmation within 1 year prior to trial entry
Mean duration of epilepsy (years): LEV 500 mg: 16.4 (SD 10.9); LEV 1000 mg: 14.5 (SD 8.9); LEV 2000 mg:
13.8 (SD 9.6); LEV 3000 mg: 15.2 (SD 10.3); PCB: 16.3 (SD 11.9)
Median baseline seizure frequency per week: LEV 500 mg: 2.67; LEV 1000 mg: 2.75; LEV 2000 mg: 3.21;
LEV 3000 mg: 2.65; PCB: 3.00






The dosage for participants assigned to LEV 500 mg/day or 1000 mg/day was not uptitrated; they re-
ceived 3 PCB tablets plus 1 LEV 250 mg (for LEV 500 mg/day) or 500 mg tablet (for LEV 1000 mg/day)
twice daily. The dosage for participants randomised to LEV 2000 mg/day or 3000 mg/day was uptitrat-
ed in the following manner: all participants received LEV 1000 mg/day (500 mg tablet twice daily) and
had their dosage increased by 1000 mg/day every 2 weeks until the target dose was reached
Outcomes ≥ 50% reduction in seizure frequency
Treatment withdrawal
Adverse effects
Notes 1 participant excluded due to drug dispensing error.
The denominators given for the 50% or greater reduction in seizure frequency outcomes were 68 for
LEV 500 mg, 68 for LEV 1000 mg, 68 for LEV 2000 mg, 69 for LEV 3000 mg, and 69 for PCB. These were
fewer participants than were randomised to each of these groups (see above) and it was unclear what
the outcomes were for each of the unreported participants. This resulted in the study being graded as
high risk for incomplete outcome data biases. The missing participants contribute to our best-case and
worst-case analyses.
Inoue 2015  (Continued)
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method not specified.
Allocation concealment
(selection bias)





Unclear risk Method not specified.
Blinding of outcome as-
sessment (detection bias)
All outcomes




High risk 1 randomised participant excluded due to drug dispensing error. It was un-
clear to which group they were assigned or their outcome. The denominators
given for the 50% or greater reduction in seizure frequency outcomes were 68
for LEV 500 mg, 68 for LEV 1000 mg, 68 for LEV 2000 mg, 69 for LEV 3000 mg,
and 69 for PCB. These were fewer participants than were randomised to each
of these groups (see above) and it was unclear what the outcomes were for
each of the unreported participants.
Selective reporting (re-
porting bias)






Methods Randomised, double-blind, PCB-controlled trial
Multicentre (28) across the US, Canada, and South Africa
2 treatment arms: 1 LEV and 1 PCB
Randomisation concealment: method not stated. Random list generation: no explicit statement of se-
quence-generation method, but participants were randomised either to LEV or PCB in a 2:1 ratio. Ran-
domisation was stratified for age (4–7 years, 8–12 years, 13–16 years) and number of concomitant AEDs
(1 or 2).
Blinding: descried as double-blind without further specification aside from stating that neurocognitive
testing was carried out by the same experienced, blinded neuropsychologist.
Baseline: 4 weeks historical, 1 week prospective. Treatment period: 12 weeks (4 weeks' titration, 8
weeks' maintenance)
Participants All children
Total randomised 98 children
64 children to LEV 60 mg/kg/day; 34 children to PCB
61% boys in LEV; 50% boys in PCB
Levisohn 2009 
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Age range: 4.1–16.7 years
Other AEDs: 1 or 2
≥ 1 focal seizure during 4 weeks before screening
Diagnosis of focal epilepsy made ≥ 6 months before screening
Mean duration of epilepsy (years): not given
Median baseline seizure frequency per week: LEV: 0.9 (IQR 0.4–1.9); PCB: 1.4 (IQR 0.4–5.2)
Interventions LEV 60 mg/kg/day
PCB add-on
Uptitration dosages: 20 mg/kg/day orally twice daily as tablets or 10% solution, uptitrated in incre-
ments of 20 mg/kg/day every 2 weeks




Behavioural and emotional functioning
Notes Cognitive assessment using Leiter-R AM, WRAML-2, and Leiter-R ERS.
Behavioural and emotional functioning assessed using CBCL and CHQ-PF50.
Cognitive, behavioural, and emotional function results shown only for the per-protocol population: 46
in LEV, 27 in PCB.
A few participants had generalised-onset (1 in LEV, 1 in PCB) or unclassified seizures (1 in PCB), or both,
in addition to partial-onset seizures.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method not stated.
Allocation concealment
(selection bias)





Unclear risk Method not stated.
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk 99 participants randomised, with 1 (1%) randomised participant not analysed.
A clear reason was given that this was because they had not taken any study
medication although their outcome was not clarified. Overall, this was un-
Levisohn 2009  (Continued)
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likely to have introduced bias. All other participants included in the ITT were
analysed in the groups they were initially assigned.
Selective reporting (re-
porting bias)






Methods Randomised, double-blind, PCB-controlled trial
Multicentre: 7 centres in Finland, India, Mexico, Russia, South Africa, and Ukraine
2 treatment arms: 1 LEV XR and 1 PCB
Randomisation concealment: interactive voice response system. Random list generation: randomised
1:1 using interactive voice response system.
Blinding: identical tablets and packages, all study personnel and participants were described as being
blinded to treatment assignment.
Baseline: 8 weeks. Treatment period: 12 weeks (no uptitration took place)
Participants All adults
Total randomised: 158 adults
79 adults to LEV XR 1000 mg; 79 adults to PCB
66% men in LEV XR; 59% men in PCB
Age range 12–70 years
Other AEDs 1–3
≥ 8 focal seizures during 8-week baseline within which ≥ 2 focal seizures per 4 weeks
Diagnosis of uncontrolled focal epilepsy made ≥ 6 months before screening
Mean duration of epilepsy (years): LEV XR 13.11 (SD 10.87) (range 0.8–42.6); PCB: 16.43 (SD 11.93) (range
0.7–53.5)
Mean baseline seizure frequency per week: LEV XR: 40.7 (SD 66.0); PCB: 30.6 (SD 52.5)
Interventions LEV XR 1000 mg
PCB
Outcomes ≥ 50% reduction in seizure frequency
Treatment withdrawal
Adverse effects
Notes 2 participants randomised to LEV XR did not receive any medication; therefore, they were excluded
from the safety population, leaving 77 participants treated with LEV XR and 79 treated with PCB in the
safety analysis dataset. Baseline level for determining reduction in seizure frequency was derived from
74 participants in LEV XR group and 78 in PCB group. A few participants had other seizure types in addi-
tion to partial-onset seizures. "Study personnel" were taken to mean investigators.
Peltola 2009 
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Participants randomised 1:1 (using an interactive voice response system) to
receive either the targeted dose of 1000 mg/day LEV XR (as 2 × 500 mg oral
tablets) or 2 matching PCB tablets once-daily (each evening).
Allocation concealment
(selection bias)





Low risk Both LEV XR 500 mg and PCB tablets were identical in shape, size, taste, and
colour, and all study personnel and participants were blinded to treatment as-
signment.
Blinding of outcome as-
sessment (detection bias)
All outcomes














Methods Randomised, double-blind, PCB-controlled, crossover trial
Multicentre across Europe
3 treatment arms: 2 LEV and 1 PCB
Randomisation concealment: allocated sequentially sealed, numbered packages containing either LEV
or PCB. Random list generation: random permuted blocks (size 6)
Blinding: identical tablets and packages. Investigators and staG were described as blinded to treatment
assignment. If treatment code was broken, the participant had to be removed from the trial.
Baseline: 8–12 weeks. Treatment period: 16 weeks (4 weeks' titration, 12 weeks' maintenance)
Participants All adults
Total randomised 324 adults; all with drug-resistant focal epilepsy but few also had generalised-onset
or unclassified seizures, or both.
106 adults to LEV 1000 mg; 106 adults to LEV 2000 mg; 112 adults to PCB
49% men
Age range: 14–69 years
Other AEDs: 1 or 2
≥ 4 focal seizures per 4 weeks during 8- or 12-week baseline
Shorvon 2000 
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≥ 2-year history of uncontrolled focal epilepsy
Mean duration of epilepsy (years): LEV 1000 mg: 23.8 (SD 12.3); LEV 2000 mg: 23.6 (SD 13.3); PCB: 23.2
(SD 11.0); overall: 23.6 (SD 12.2)
Mean baseline seizure frequency per week: 2.62; range: 0.3–102.7
Interventions LEV 1000 mg
LEV 2000 mg
PCB
Uptitration dosages: LEV was titrated upwards in twice-daily increments of 500 mg at 2-week intervals
until participants were stabilised on their assigned dosages (1000 mg/day or 2000 mg/day). The 1000-
mg LEV group received PCB for 2 weeks before initiation of active drug
Outcomes ≥ 50% reduction in seizure frequency
Treatment withdrawal
Adverse effects
QoL and cognitive effects
Notes A few participants had generalised-onset or unclassified seizures, or both, in addition to partial-onset
seizures.
QoL assessed using the ESI-55 for 92 participants each in LEV 1000 mg and LEV 2000 mg groups, and 89
participants in PCB group.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Random permuted blocks (size 6).
Allocation concealment
(selection bias)






Low risk Identical tablets and packages.
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk All participants randomised into the ITT were analysed in the groups they were
initially assigned to according to the published data, although in the unpub-
lished protocols 2 participants were said to have been excluded from 50% re-
sponder analysis: 1 in LEV 2000 mg; 1 in PCB. Overall, this was unlikely to have




Low risk All outcomes measured (that were also relevant to this review) were pub-
lished.
Shorvon 2000  (Continued)
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Methods Randomised, double-blind, PCB-controlled trial
Multicentre in Taiwan
2 treatment arms: 1 LEV and 1 PCB
Randomisation concealment: allocated sequentially sealed, numbered packages containing either LEV
or PCB. Random list generation: random permuted blocks (size 4).
Blinding: identical tablets and packages. Investigators were described as blinded to treatment assign-
ment.
Baseline: 8 weeks. Treatment period: 14 weeks (2 weeks' titration, 12 weeks' maintenance)
Participants All adults
Total randomised 94 adults
47 adults to LEV 2000 mg; 47 adults to PCB
36% men in LEV; 53% men in PCB
Age range: 16–60 years
Other AEDs: 1–3
≥ 4 focal seizures during 8-week baseline
Diagnosis of uncontrolled focal epilepsy made ≥ 6 months before study
Mean duration of epilepsy (years): LEV: 18.6 (SD 8.5); PCB: 18.7 (SD 10.7)
Mean baseline seizure frequency per week: LEV: 4.0 (SD 14.1); PCB: 4.3 (SD 7.0)
Interventions LEV 2000 mg/day
PCB
Uptitration dosages: initial LEV dose was 500 mg twice daily, which was increased to 1000 mg twice dai-
ly after 2 weeks.
Outcomes ≥ 50% reduction in seizure frequency
Treatment withdrawal
Adverse effects
Notes 1 participant (LEV group) excluded from 50% responder analysis.
A minority of participants also had generalised or unclassified, or both, seizures in addition to par-
tial-onset seizures.
14 participants required dose reduction (11 in LEV; 3 in PCB).
Risk of bias
Bias Authors' judgement Support for judgement
Tsai 2006 
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Random sequence genera-
tion (selection bias)
Low risk The random treatment-allocation sequence was generated in Belgium by the
Clinical Drug Supply Unit of the sponsor on 22 May 2000, by using a randomi-










Low risk Study drug containers were labelled in Belgium by the sponsor using an identi-
cal method for both treatments.
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk 1 participant (LEV group) excluded from 50% responder analysis because they
had missing data for weekly frequency of partial seizures. This reason for miss-
ing outcome data was unlikely to be related to true outcome. Remaining ran-
domised participants were analysed in the group they were assigned.
Selective reporting (re-
porting bias)






Methods Randomised, double-blind, PCB-controlled trial
Multicentre, 6 centres in China
2 treatment arms: 1 LEV and 1 PCB
Randomisation concealment: method not stated. Study medications were supplied and packaged by
UCB S.A. Pharma.
Method of sequence generation: not stated.
Blinding: "matched placebo" was used. No further specification.
Baseline: 8 weeks. Treatment period: 16 weeks (4 weeks' titration, 12 weeks' maintenance)
Participants All adults
Total randomised 206 adults
103 adults to LEV; 103 adults to PCB
50% men in LEV; 54% men in PCB
Age range: 16–70 years
Other AEDs: 1 or 2
≥ 8 focal seizures during 8-week baseline
Diagnosis of focal epilepsy made ≥ 6 months before screening
Wu 2009 
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Mean duration of epilepsy (years): LEV: 16.5 (SD 12.7); PCB: 17.3 (SD 12.1)
Median baseline seizure frequency per week: LEV 1.81 (IQR 1.13–3.38); PCB 1.75 (IQR 1.13–4.00)
Interventions LEV 3000 mg
PCB
Uptitration dosages: started with 500 mg (1 tablet) twice daily and was uptitrated in twice-daily incre-
ments of 500 mg (1 tablet) at 2-week intervals; the dose was increased to 2000 mg/day after 2 weeks
and to 3000 mg/day after an additional 2 weeks.
Outcomes ≥ 50% reduction in seizure frequency
Treatment withdrawal
Adverse effects
Notes 4 participants excluded from 50% responder analysis: 1 in LEV 3000 mg (lost to follow-up) and 3 in PCB
(2 lost to follow-up and 1 adverse effect).
A few participants (1 in LEV, 2 in PCB) had primary generalised-onset seizures in addition to partial-on-
set seizures. 1 participant (1.0%) in the LEV group and 2 (1.9%) in the PCB group temporarily discon-
tinued the study drug, while 8 (7.8%) in the LEV and 2 (1.9%) in the PCB groups reduced the dosage be-
cause of adverse events.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method not given.
Allocation concealment
(selection bias)





Low risk "Matched placebo" was used. No further specification.
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk 4 participants excluded from 50% responder analysis: 1 in LEV 3000 mg (lost to
follow-up) and 3 in PCB (2 lost to follow-up and 1 adverse effect). The reasons
for missing outcome data may possibly be related to true outcome (e.g. lost to
follow-up due to improvement), but these reasons are largely equally distrib-
uted between the intervention groups.
Selective reporting (re-
porting bias)
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Methods Randomised, double-blind, PCB-controlled trial
Single centre in China
2 treatment arms: 1 LEV and 1 PCB
Randomisation concealment: numbered containers containing either LEV or PCB. Random list genera-
tion: randomisation codes were generated by the study sponsor. Each participant who qualified to re-
ceive double-blind treatment was assigned a randomisation number and given LEV or PCB accordingly.
Blinding: identical tablets and packages. Investigators were described as blinded to treatment assign-
ment.
Baseline: 8 weeks. Treatment period: 16 weeks (4 weeks' titration, 12 weeks' maintenance)
Participants All adults
Total randomised 56 adults; all with drug-resistant focal epilepsy
28 adults to LEV 3000 mg; 28 adults to PCB
42.9% men in LEV; 42.9% men in PCB
Age range: 16–70 years
Other AEDs: 1 or 2
≥ 4 focal seizures per month over preceding 2 months
≥ 10 weeks' background AED treatment
Mean duration of epilepsy (years): LEV: 14.1 (SD 9.4) (range 2–40); PCB: 16.1 (SD 12.5) (range 2–48)
Mean baseline seizure frequency per week: LEV 4.9 (range 1–23.6); PCB 5.6 (range 1–50)
Interventions LEV 3000 mg/day
PCB
Uptitration dosages: received LEV 1000 mg/day (administered twice daily) and increased to 2000 mg/
day after 2 weeks, and to 3000 mg/day after another 2 weeks
Outcomes ≥ 50% reduction in seizure frequency
Treatment withdrawal
Adverse effects
Notes 2 LEV-treated participants decreased dose to 2000 mg (owing to adverse effects).
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomisation codes generated by study sponsor.
Allocation concealment
(selection bias)




Low risk Identical tablets and packages.
Xiao 2009  (Continued)
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All outcomes
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk All participants randomised were analysed in the group they were assigned.
Selective reporting (re-
porting bias)






Methods Randomised, double-blind, PCB-controlled, parallel trial
Multicentre in Japan
3 treatment arms: 2 LEV and 1 PCB
Randomisation concealment: method not stated.
Random list generation: method not stated.
Blinding: method not stated.
Baseline: 12 weeks. Treatment period: 16 weeks (4 weeks' titration, 12 weeks' maintenance)
Participants All adults
Total randomised 216 adults
73 adults to LEV 1000 mg/day; 71 adults to LEV 3000 mg/day; 72 adults to PCB
51.2% men
Age range: 16–65 years
Other AEDs: 1–3
Mean duration of epilepsy (years): LEV 1000 mg/day: 23.05 (SD 10.80); LEV 3000 mg/day: 20.79 (SD
10.80); PCB: 22.54 (SD 11.57)
Median baseline seizure frequency per week: LEV 1000 mg/day: 3.66 (IQR 1.75–6.71); LEV 3000 mg/day
3.21 (IQR 1.93–6.54); PCB: 2.61 (IQR 1.93–5.38)
Interventions LEV 1000 mg/day
LEV 3000 mg/day
PCB
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Notes The numbers randomised to ITT were 73 LEV 1000 mg/day; 71 LEV 3000 mg; and 72 PCB, but in the
analysis the denominators were 64 LEV 1000 mg/day; 63 LEV 3000 mg/day; and 65 PCB. It was reported
that 2 participants were not analysed due to misallocation from PCB and 1 from LEV 1000 mg/day due
to no study medication taken. The reasons for exclusion from analysis and outcomes of the remaining
missing participants were not clear.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method not stated.
Allocation concealment
(selection bias)





Unclear risk Method not stated.
Blinding of outcome as-
sessment (detection bias)
All outcomes




High risk Denominators changing in the analysis section with large numbers of missing
participant data between those randomised and those actually analysed.
Selective reporting (re-
porting bias)





Methods Randomised, double-blind, PCB-controlled trial
Single centre in China
2 treatment arms: 1 LEV and 1 PCB
Randomisation concealment: method not stated
Random list generation: method not stated
Blinding: method not stated
Baseline: 8 weeks. Treatment period: 16 weeks (4 weeks' titration, 12 weeks' maintenance)
Participants All adults
Total randomised 30 adults, 3 dropouts, 27 completed the trial; all with drug-resistant focal epilepsy
18 adults to LEV; 9 adults to PCB
61.1% men in LEV; could not determine % men in PCB
Age range: could not determine
Zheng 2009 
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Other AEDs: 1–4
≥ 8 focal seizures during 8-week baseline
≥ 12 weeks' background AED treatment
Mean duration of epilepsy: not stated
Mean baseline seizure frequency per year: unknown
Interventions LEV 3000 mg/day
PCB




3 participants quit the trial before measurement (1 for adverse effects and 2 because they thought
treatment was invalid). It is unclear which treatment groups the participants withdrew from.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method not stated.
Allocation concealment
(selection bias)





Unclear risk Method not stated.
Blinding of outcome as-
sessment (detection bias)
All outcomes




High risk 3 participants quit the trial before measurement (1 for adverse effects and 2
because they thought treatment was invalid). It was unclear to which groups
they were randomised. These reasons for missing outcome data were likely re-
lated to true outcome, and in a small study such as this, such incomplete out-
come data would be likely to introduce bias.
Selective reporting (re-
porting bias)






Methods Randomised, double-blind, PCB-controlled trial
Zhou 2008 
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Single centre in China
2 treatment arms: 1 LEV and 1 PCB
Randomisation concealment: participants received an exclusive random number consecutively on en-
try into the study, and received treatment on the basis of this random number. Random list generation:
random numbers table.
Blinding: described as double-blind with no further specification. Medications were supplied and pack-
aged by UCB S.A. Pharma.
Baseline: 8 weeks. Treatment period: 16 weeks (4 weeks' titration, 12 weeks' maintenance)
Participants All adults. Total randomised 28 adults
14 adults to LEV 3000 mg; 14 adults to PCB
54% men in LEV; 55% men in PCB
Age range: 16–70 years
Other AEDs: 1–2
≥ 8 seizures during 8-week baseline with 2 per 4 weeks
Mean duration of epilepsy (years): LEV: 8.7 (SD 6.4); PCB 16.5 SD 7.2)
Mean baseline seizure frequency per week: LEV: 6.55 (SD 10.79); PCB: 6.15 (SD 11.20)
Interventions LEV 3000 mg/day
PCB add-on
Uptitration dosages: 500 mg twice daily in the first 2 weeks, 1000 mg twice daily in the third and fourth
weeks)




Notes Cognitive function assessment using a battery of neuropsychological tests: Wisconsin Card Sorting
Test, Verbal Fluency, Trail Making Test, Digit Symbol, Stroop Color–Word Interference Task, Logic Mem-
ory, Delayed Logic Memory, Visual Memory, Delayed Visual Memory, Calculation.
QoL assessment using QOLIE-31
Dropouts (1 in LEV, 3 in PCB) excluded from the study author's analysis.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Random numbers table used.
Allocation concealment
(selection bias)
Low risk Participants received an exclusive random number consecutively on entry into
the study, and received treatment on the basis of that random number.
Zhou 2008  (Continued)
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Unclear risk Described as double-blind with no further specification.
Blinding of outcome as-
sessment (detection bias)
All outcomes




High risk 4 participants (1 from LEV group and 3 from PCB group) withdrew from the tri-
al due to non-compliance. They were not analysed and their outcomes were
not stated. The reasons for missing outcome data here were likely to be relat-




Low risk All outcomes measured (that were also relevant to this review) were pub-
lished.
Zhou 2008  (Continued)
AED: antiepileptic drug; CBCL: Achenbach Child Behavior Checklist; CHQ-PF50: Child Health Questionnaire-Parent Form 50; EEG:
electroencephalography; ESI-55: Epilepsy Surgery Inventory scale; IQR: interquartile range; ITT: intention to treat; Leiter-R AM: Leiter
International Performance Scale-Revised Attention and Memory; Leiter-R ERS: Leiter International Performance Scale-Revised, Examiner’s
Rating Scale; LEV: levetiracetam; PCB: placebo; QoL: quality of life; QOLIE: Quality Of Life In Epilepsy inventory; SD: standard deviation;
WRAML-2: Wide Range Assessment of Memory and Learning-2; XR: extended release.
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Boon 2002 Cross-over trial where separate data pertaining to the first treatment period only were not avail-
able. Therefore, could not analyse the first treatment period as if it were a parallel trial (see Unit of
analysis issues).
 
Characteristics of studies awaiting classification [ordered by study ID]
 
Methods Double-blind, phase III, multicentre, randomised, PCB-controlled, parallel trial
2 treatment arms: 1 LEV; 1 PCB
Randomisation concealment: described as concealed, method not given.
Random list generation: described as randomised, method not given.
Blinding: participant, care provider, investigator, outcomes assessor stated as blinded. Method not
given.
Baseline: not stated. Treatment period: 24 weeks (titration and maintenance period not stated)
Participants 126 participants
Numbers randomised to each arm: unknown
Sex: unknown
Eligible age range: 4–65 years
NCT01392768 
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Other AEDs: 1–3
≥ 4 focal seizures per month over preceding 2 months
≥ 2-year history of seizures
Mean duration of epilepsy: unknown
Mean baseline seizure frequency per week: unknown
Interventions LEV
PCB
Outcomes ≥ 50% reduction in seizure frequency
Treatment withdrawal
Adverse effects
Notes Results not yet posted.
NCT01392768  (Continued)
AED: antiepileptic drug; LEV: levetiracetam; PCB: placebo.
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Levetiracetam versus placebo





Statistical method Effect size
1.1 ≥ 50% reduction in focal seizure fre-
quency: intention to treat
14   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1.1 60 mg/kg/day 2 296 Risk Ratio (M-H, Fixed, 95% CI) 1.91 [1.38, 2.63]
1.1.2 500 mg 1 141 Risk Ratio (M-H, Fixed, 95% CI) 1.60 [0.71, 3.62]
1.1.3 1000 mg 5 854 Risk Ratio (M-H, Fixed, 95% CI) 2.30 [1.72, 3.06]
1.1.4 2000 mg 4 533 Risk Ratio (M-H, Fixed, 95% CI) 3.26 [2.16, 4.94]
1.1.5 3000 mg 8 1082 Risk Ratio (M-H, Fixed, 95% CI) 2.59 [2.07, 3.23]
1.1.6 4000 mg 1 77 Risk Ratio (M-H, Fixed, 95% CI) 1.64 [0.59, 4.57]
1.1.7 All doses 14 2455 Risk Ratio (M-H, Fixed, 95% CI) 2.37 [2.02, 2.78]
1.2 ≥ 50% reduction in focal seizure fre-
quency: intention to treat (random ef-
fects)
14   Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.2.1 1000 mg 5 854 Risk Ratio (M-H, Random, 95% CI) 2.31 [1.43, 3.75]
1.2.2 2000 mg 4 533 Risk Ratio (M-H, Random, 95% CI) 2.98 [1.59, 5.60]
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1.2.3 3000 mg 8 1082 Risk Ratio (M-H, Random, 95% CI) 2.49 [1.80, 3.45]
1.2.4 All doses 14 2455 Risk Ratio (M-H, Random, 95% CI) 2.26 [1.79, 2.85]
1.3 ≥ 50% reduction in focal seizure fre-
quency: (intention to treat): subgroup
analysis by age
14   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.3.1 Children 2 296 Risk Ratio (M-H, Fixed, 95% CI) 1.91 [1.38, 2.63]
1.3.2 Adults (all doses) 12 2159 Risk Ratio (M-H, Fixed, 95% CI) 2.49 [2.08, 2.99]
1.4 ≥ 50% reduction in focal seizure fre-
quency: (intention to treat): subgroup
analysis by age (random effects)
12   Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.4.1 Adults (all doses) 12 2159 Risk Ratio (M-H, Random, 95% CI) 2.40 [1.82, 3.16]
1.5 ≥ 50% reduction in focal seizure fre-
quency: best case
14   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.5.1 60 mg/kg/day 2 296 Risk Ratio (M-H, Fixed, 95% CI) 1.91 [1.38, 2.63]
1.5.2 500 mg 1 141 Risk Ratio (M-H, Fixed, 95% CI) 1.97 [0.90, 4.31]
1.5.3 1000 mg 5 854 Risk Ratio (M-H, Fixed, 95% CI) 2.59 [1.96, 3.43]
1.5.4 2000 mg 4 533 Risk Ratio (M-H, Fixed, 95% CI) 4.00 [2.67, 5.99]
1.5.5 3000 mg 8 1082 Risk Ratio (M-H, Fixed, 95% CI) 2.81 [2.26, 3.50]
1.5.6 4000 mg 1 77 Risk Ratio (M-H, Fixed, 95% CI) 3.69 [1.53, 8.95]
1.5.7 All doses 14 2455 Risk Ratio (M-H, Fixed, 95% CI) 2.63 [2.25, 3.09]
1.6 ≥ 50% reduction in focal seizure fre-
quency: worst case
14   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.6.1 60 mg/kg/day 2 296 Risk Ratio (M-H, Fixed, 95% CI) 1.91 [1.38, 2.63]
1.6.2 500 mg 1 141 Risk Ratio (M-H, Fixed, 95% CI) 1.42 [0.65, 3.12]
1.6.3 1000 mg 5 854 Risk Ratio (M-H, Fixed, 95% CI) 1.94 [1.48, 2.53]
1.6.4 2000 mg 4 533 Risk Ratio (M-H, Fixed, 95% CI) 2.31 [1.62, 3.30]
1.6.5 3000 mg 8 1082 Risk Ratio (M-H, Fixed, 95% CI) 2.14 [1.75, 2.62]
1.6.6 4000 mg 1 77 Risk Ratio (M-H, Fixed, 95% CI) 0.63 [0.30, 1.35]
1.6.7 All doses 14 2455 Risk Ratio (M-H, Fixed, 95% CI) 1.99 [1.72, 2.30]
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Statistical method Effect size
1.7 ≥ 50% reduction in focal seizure fre-
quency: best case (random effects)
14   Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.7.1 1000 mg 5 854 Risk Ratio (M-H, Random, 95% CI) 2.63 [1.67, 4.14]
1.7.2 3000 mg 8 1082 Risk Ratio (M-H, Random, 95% CI) 2.74 [1.96, 3.82]
1.7.3 All doses 14 2455 Risk Ratio (M-H, Random, 95% CI) 2.55 [1.99, 3.27]
1.8 ≥ 50% reduction in focal seizure fre-
quency: worst case (random effects)
14   Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.8.1 1000 mg 5 854 Risk Ratio (M-H, Random, 95% CI) 1.94 [1.17, 3.21]
1.8.2 2000 mg 4 533 Risk Ratio (M-H, Random, 95% CI) 2.14 [0.89, 5.11]
1.8.3 3000 mg 8 1082 Risk Ratio (M-H, Random, 95% CI) 2.03 [1.45, 2.84]
1.8.4 All doses 14 2455 Risk Ratio (M-H, Random, 95% CI) 1.87 [1.45, 2.41]
1.9 ≥ 50% reduction in focal seizure fre-
quency: sensitivity analysis with trials of
low risk of bias only
5   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.9.1 Intention to treat 5 1156 Risk Ratio (M-H, Fixed, 95% CI) 2.93 [2.25, 3.81]
1.9.2 Best-case scenario 5 1156 Risk Ratio (M-H, Fixed, 95% CI) 3.13 [2.41, 4.06]
1.9.3 Worst-case scenario 5 1156 Risk Ratio (M-H, Fixed, 95% CI) 2.69 [2.09, 3.46]
1.10 ≥ 50% reduction in focal seizure fre-
quency: sensitivity analysis with trials of
low risk of bias only (random effects)
6   Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.10.1 Intention to treat 6 1354 Risk Ratio (M-H, Random, 95% CI) 2.81 [1.88, 4.19]
1.10.2 Best-case scenario 6 1354 Risk Ratio (M-H, Random, 95% CI) 2.95 [2.02, 4.31]
1.10.3 Worst-case scenario 6 1354 Risk Ratio (M-H, Random, 95% CI) 2.65 [1.79, 3.92]
1.11 Treatment withdrawal 13   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.11.1 60 mg/kg/day 2 296 Risk Ratio (M-H, Fixed, 95% CI) 0.80 [0.43, 1.46]
1.11.2 500 mg 1 141 Risk Ratio (M-H, Fixed, 95% CI) 2.96 [0.84, 10.47]
1.11.3 1000 mg 5 854 Risk Ratio (M-H, Fixed, 95% CI) 1.23 [0.85, 1.79]
1.11.4 2000 mg 4 533 Risk Ratio (M-H, Fixed, 95% CI) 1.49 [0.97, 2.28]
1.11.5 3000 mg 7 1055 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.79, 1.57]
1.11.6 4000 mg 1 77 Risk Ratio (M-H, Fixed, 95% CI) 0.92 [0.42, 2.02]
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Statistical method Effect size
1.11.7 Any dose 13 2428 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.89, 1.40]
1.12 Treatment withdrawal: subgroup
analysis by age
13   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.12.1 Children 2 296 Risk Ratio (M-H, Fixed, 95% CI) 0.80 [0.43, 1.46]
1.12.2 Adults 11 2132 Risk Ratio (M-H, Fixed, 95% CI) 1.18 [0.92, 1.51]
1.13 Treatment withdrawal: subgroup
analysis by age (random effects)
2   Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.13.1 Children 2 296 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.28, 2.52]
1.14 Treatment withdrawal: sensitivity
analysis with trials of low risk of bias only
5 1156 Risk Ratio (M-H, Fixed, 95% CI) 1.26 [0.90, 1.76]
1.15 Treatment withdrawal: sensitivity
analysis with trials of low risk of bias only
(random effects)
5 1156 Risk Ratio (M-H, Random, 95% CI) 1.24 [0.89, 1.74]
1.16 Adverse effects: 5 most common ad-
verse effects (any age)
13   Risk Ratio (M-H, Fixed, 99% CI) Subtotals only
1.16.1 Somnolence 13 2425 Risk Ratio (M-H, Fixed, 99% CI) 1.62 [1.19, 2.20]
1.16.2 Headache 13 2425 Risk Ratio (M-H, Fixed, 99% CI) 0.85 [0.59, 1.21]
1.16.3 Dizziness 13 2425 Risk Ratio (M-H, Fixed, 99% CI) 1.54 [0.98, 2.41]
1.16.4 Fatigue (asthenia) 13 2425 Risk Ratio (M-H, Fixed, 99% CI) 1.53 [0.98, 2.38]
1.16.5 Accidental injury 13 2425 Risk Ratio (M-H, Fixed, 99% CI) 0.72 [0.49, 1.06]
1.17 Adverse effects: 5 most common ad-
verse effects (any age, random effects)
13   Risk Ratio (M-H, Random, 99% CI) Subtotals only
1.17.1 Headache 13 2425 Risk Ratio (M-H, Random, 99% CI) 0.74 [0.38, 1.47]
1.17.2 Accidental injury 13 2425 Risk Ratio (M-H, Random, 99% CI) 0.69 [0.35, 1.36]
1.18 Adverse effects: most common ad-
verse effects in adults
10   Risk Ratio (M-H, Fixed, 99% CI) Subtotals only
1.18.1 Accidental injury 4 1023 Risk Ratio (M-H, Fixed, 99% CI) 0.60 [0.39, 0.92]
1.18.2 Ataxia (unpublished data only) 4 1023 Risk Ratio (M-H, Fixed, 99% CI) 1.50 [0.43, 5.26]
1.18.3 Dizziness 9 1813 Risk Ratio (M-H, Fixed, 99% CI) 1.55 [0.95, 2.51]
1.18.4 Fatigue (asthenia) 4 1023 Risk Ratio (M-H, Fixed, 99% CI) 1.47 [0.90, 2.40]
1.18.5 Headache 7 1711 Risk Ratio (M-H, Fixed, 99% CI) 0.78 [0.54, 1.14]
Levetiracetam add-on for drug-resistant focal epilepsy (Review)









Cochrane Database of Systematic Reviews





Statistical method Effect size
1.18.6 Infection 4 1023 Risk Ratio (M-H, Fixed, 99% CI) 1.76 [1.03, 3.02]
1.18.7 Nausea 3 599 Risk Ratio (M-H, Fixed, 99% CI) 1.37 [0.47, 4.00]
1.18.8 Somnolence 10 2099 Risk Ratio (M-H, Fixed, 99% CI) 1.57 [1.13, 2.20]
1.19 Adverse effects: most common ad-
verse effects in children
2   Risk Ratio (M-H, Fixed, 99% CI) Subtotals only
1.19.1 Accidental injury 1 198 Risk Ratio (M-H, Fixed, 99% CI) 1.63 [0.63, 4.26]
1.19.2 Aggression (hostility) 2 296 Risk Ratio (M-H, Fixed, 99% CI) 1.72 [0.64, 4.63]
1.19.3 Cough 2 296 Risk Ratio (M-H, Fixed, 99% CI) 1.39 [0.49, 3.93]
1.19.4 Dizziness 2 296 Risk Ratio (M-H, Fixed, 99% CI) 1.52 [0.47, 4.94]
1.19.5 Fatigue (asthenia) 2 296 Risk Ratio (M-H, Fixed, 99% CI) 1.82 [0.62, 5.33]
1.19.6 Pharyngitis 2 296 Risk Ratio (M-H, Fixed, 99% CI) 1.09 [0.47, 2.50]
1.19.7 Somnolence 2 296 Risk Ratio (M-H, Fixed, 99% CI) 1.90 [0.88, 4.09]
1.19.8 Vomiting 2 296 Risk Ratio (M-H, Fixed, 99% CI) 1.22 [0.55, 2.69]
1.20 Behavioural changes 6   Risk Ratio (M-H, Fixed, 99% CI) Subtotals only
1.20.1 Hostility 1 198 Risk Ratio (M-H, Fixed, 99% CI) 1.92 [0.56, 6.60]
1.20.2 Personality disorder 1 198 Risk Ratio (M-H, Fixed, 99% CI) 1.10 [0.30, 3.95]
1.20.3 Nervousness 1 198 Risk Ratio (M-H, Fixed, 99% CI) 4.80 [0.68, 34.14]
1.20.4 Depression 1 324 Risk Ratio (M-H, Fixed, 99% CI) 1.41 [0.25, 7.85]
1.20.5 Aggression 1 98 Risk Ratio (M-H, Fixed, 99% CI) 1.42 [0.27, 7.42]
1.20.6 Agitation 2 254 Risk Ratio (M-H, Fixed, 99% CI) 6.17 [0.66, 57.79]
1.20.7 Emotional lability 1 198 Risk Ratio (M-H, Fixed, 99% CI) 1.44 [0.28, 7.29]
1.20.8 Psychomotor hyperactivity 1 98 Risk Ratio (M-H, Fixed, 99% CI) 0.42 [0.08, 2.19]
1.20.9 Irritability 1 156 Risk Ratio (M-H, Fixed, 99% CI) 11.28 [0.26, 495.63]
1.20.10 Abnormal behaviour 1 98 Risk Ratio (M-H, Fixed, 99% CI) 5.92 [0.14, 255.98]
1.20.11 Altered mood 1 98 Risk Ratio (M-H, Fixed, 99% CI) 4.85 [0.11, 216.99]
1.20.12 Anxiety 1 98 Risk Ratio (M-H, Fixed, 99% CI) 4.85 [0.11, 216.99]
1.20.13 Dissociation 1 94 Risk Ratio (M-H, Fixed, 99% CI) 0.14 [0.00, 6.77]
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Statistical method Effect size
1.20.14 Combined (regardless of age) 6 926 Risk Ratio (M-H, Fixed, 99% CI) 1.87 [1.19, 2.95]
1.20.15 Combined (children) 2 296 Risk Ratio (M-H, Fixed, 99% CI) 1.90 [1.16, 3.11]
1.20.16 Combined (adults) 4 630 Risk Ratio (M-H, Fixed, 99% CI) 1.79 [0.59, 5.41]
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Heterogeneity: Chi² = 1.58, df = 1 (P = 0.21); I² = 37%















Heterogeneity: Chi² = 9.91, df = 4 (P = 0.04); I² = 60%








Heterogeneity: Chi² = 6.49, df = 3 (P = 0.09); I² = 54%












Heterogeneity: Chi² = 12.57, df = 7 (P = 0.08); I² = 44%




















































































































































M-H, Fixed, 95% CI
2.27 [1.44 , 3.60]
1.52 [0.97 , 2.37]
1.91 [1.38 , 2.63]
1.60 [0.71 , 3.62]
1.60 [0.71 , 3.62]
4.99 [2.33 , 10.65]
1.50 [0.65 , 3.44]
1.48 [0.96 , 2.27]
3.32 [1.48 , 7.45]
2.19 [1.07 , 4.49]
2.30 [1.72 , 3.06]
2.41 [0.95 , 6.15]
1.38 [0.59 , 3.21]
5.58 [2.60 , 11.98]
4.00 [1.64 , 9.77]
3.26 [2.16 , 4.94]
2.59 [1.62 , 4.14]
5.37 [2.53 , 11.41]
2.88 [1.38 , 5.98]
2.19 [1.51 , 3.19]
1.18 [0.64 , 2.17]
2.03 [0.98 , 4.21]
6.50 [1.00 , 42.17]
4.00 [1.03 , 15.60]
2.59 [2.07 , 3.23]
1.64 [0.59 , 4.57]
1.64 [0.59 , 4.57]
Risk Ratio
M-H, Fixed, 95% CI
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Heterogeneity: Chi² = 24.71, df = 13 (P = 0.03); I² = 47%

















































































1.64 [0.59 , 4.57]
2.59 [1.62 , 4.14]
2.05 [0.83 , 5.02]
5.18 [2.49 , 10.80]
2.27 [1.44 , 3.60]
1.84 [0.92 , 3.66]
1.52 [0.97 , 2.37]
1.48 [0.96 , 2.27]
4.45 [2.10 , 9.42]
4.00 [1.64 , 9.77]
2.19 [1.51 , 3.19]
1.18 [0.64 , 2.17]
2.11 [1.08 , 4.12]
6.50 [1.00 , 42.17]
4.00 [1.03 , 15.60]
2.37 [2.02 , 2.78]
0.1 0.2 0.5 1 2 5 10
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Analysis 1.2.   Comparison 1: Levetiracetam versus placebo, Outcome 2: ≥ 50% reduction in focal seizure frequency:










Heterogeneity: Tau² = 0.18; Chi² = 9.91, df = 4 (P = 0.04); I² = 60%








Heterogeneity: Tau² = 0.22; Chi² = 6.49, df = 3 (P = 0.09); I² = 54%












Heterogeneity: Tau² = 0.09; Chi² = 12.57, df = 7 (P = 0.08); I² = 44%


















Heterogeneity: Tau² = 0.08; Chi² = 24.71, df = 13 (P = 0.03); I² = 47%
























































































































































































M-H, Random, 95% CI
4.99 [2.33 , 10.65]
1.50 [0.65 , 3.44]
1.48 [0.96 , 2.27]
3.32 [1.48 , 7.45]
2.19 [1.07 , 4.49]
2.31 [1.43 , 3.75]
2.41 [0.95 , 6.15]
1.38 [0.59 , 3.21]
5.58 [2.60 , 11.98]
4.00 [1.64 , 9.77]
2.98 [1.59 , 5.60]
2.59 [1.62 , 4.14]
5.37 [2.53 , 11.41]
2.88 [1.38 , 5.98]
2.19 [1.51 , 3.19]
1.18 [0.64 , 2.17]
2.03 [0.98 , 4.21]
6.50 [1.00 , 42.17]
4.00 [1.03 , 15.60]
2.49 [1.80 , 3.45]
2.59 [1.62 , 4.14]
2.05 [0.83 , 5.02]
5.18 [2.49 , 10.80]
2.27 [1.44 , 3.60]
1.84 [0.92 , 3.66]
1.52 [0.97 , 2.37]
1.48 [0.96 , 2.27]
4.45 [2.10 , 9.42]
4.00 [1.64 , 9.77]
2.19 [1.51 , 3.19]
1.18 [0.64 , 2.17]
2.11 [1.08 , 4.12]
6.50 [1.00 , 42.17]
4.00 [1.03 , 15.60]
2.26 [1.79 , 2.85]
Risk Ratio
M-H, Random, 95% CI
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Analysis 1.2.   (Continued)
Test for overall effect: Z = 6.90 (P < 0.00001)
0.01 0.1 1 10 100
Placebo better Levetiracetam better
 
 
Analysis 1.3.   Comparison 1: Levetiracetam versus placebo, Outcome 3: ≥ 50%







Heterogeneity: Chi² = 1.58, df = 1 (P = 0.21); I² = 37%
Test for overall effect: Z = 3.94 (P < 0.0001)















Heterogeneity: Chi² = 21.83, df = 11 (P = 0.03); I² = 50%
Test for overall effect: Z = 9.80 (P < 0.00001)

























































































M-H, Fixed, 95% CI
2.27 [1.44 , 3.60]
1.52 [0.97 , 2.37]
1.91 [1.38 , 2.63]
2.59 [1.62 , 4.14]
2.05 [0.83 , 5.02]
5.18 [2.49 , 10.80]
1.84 [0.92 , 3.66]
1.48 [0.96 , 2.27]
4.45 [2.10 , 9.42]
4.00 [1.64 , 9.77]
2.19 [1.51 , 3.19]
1.18 [0.64 , 2.17]
2.11 [1.08 , 4.12]
6.50 [1.00 , 42.17]
4.00 [1.03 , 15.60]
2.49 [2.08 , 2.99]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Placebo better Levetiracetam better
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Analysis 1.4.   Comparison 1: Levetiracetam versus placebo, Outcome 4: ≥ 50% reduction
in focal seizure frequency: (intention to treat): subgroup analysis by age (random e7ects)
Study or Subgroup















Heterogeneity: Tau² = 0.10; Chi² = 21.83, df = 11 (P = 0.03); I² = 50%










































































M-H, Random, 95% CI
2.59 [1.62 , 4.14]
2.05 [0.83 , 5.02]
5.18 [2.49 , 10.80]
1.84 [0.92 , 3.66]
1.48 [0.96 , 2.27]
4.45 [2.10 , 9.42]
4.00 [1.64 , 9.77]
2.19 [1.51 , 3.19]
1.18 [0.64 , 2.17]
2.11 [1.08 , 4.12]
6.50 [1.00 , 42.17]
4.00 [1.03 , 15.60]
2.40 [1.82 , 3.16]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Placebo better Levetiracetam better
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Heterogeneity: Chi² = 1.58, df = 1 (P = 0.21); I² = 37%















Heterogeneity: Chi² = 9.30, df = 4 (P = 0.05); I² = 57%








Heterogeneity: Chi² = 5.92, df = 3 (P = 0.12); I² = 49%












Heterogeneity: Chi² = 13.49, df = 7 (P = 0.06); I² = 48%




















































































































































M-H, Fixed, 95% CI
2.27 [1.44 , 3.60]
1.52 [0.97 , 2.37]
1.91 [1.38 , 2.63]
1.97 [0.90 , 4.31]
1.97 [0.90 , 4.31]
5.12 [2.40 , 10.92]
1.75 [0.78 , 3.91]
1.65 [1.09 , 2.50]
3.32 [1.48 , 7.45]
3.18 [1.62 , 6.23]
2.59 [1.96 , 3.43]
5.20 [2.23 , 12.12]
1.63 [0.72 , 3.67]
5.74 [2.68 , 12.28]
4.20 [1.73 , 10.20]
4.00 [2.67 , 5.99]
2.93 [1.85 , 4.65]
5.37 [2.53 , 11.41]
3.13 [1.52 , 6.45]
2.23 [1.54 , 3.24]
1.18 [0.64 , 2.17]
2.93 [1.48 , 5.80]
6.50 [1.00 , 42.17]
4.50 [1.18 , 17.21]
2.81 [2.26 , 3.50]
3.69 [1.53 , 8.95]
3.69 [1.53 , 8.95]
Risk Ratio
M-H, Fixed, 95% CI
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Heterogeneity: Chi² = 28.93, df = 13 (P = 0.007); I² = 55%

















































































3.69 [1.53 , 8.95]
2.93 [1.85 , 4.65]
4.49 [1.94 , 10.39]
5.25 [2.52 , 10.94]
2.27 [1.44 , 3.60]
2.12 [1.07 , 4.20]
1.52 [0.97 , 2.37]
1.65 [1.09 , 2.50]
4.53 [2.14 , 9.57]
4.20 [1.73 , 10.20]
2.23 [1.54 , 3.24]
1.18 [0.64 , 2.17]
3.06 [1.60 , 5.83]
6.50 [1.00 , 42.17]
4.50 [1.18 , 17.21]
2.63 [2.25 , 3.09]
0.1 0.2 0.5 1 2 5 10
Placebo better Levetiracetam better
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Heterogeneity: Chi² = 1.58, df = 1 (P = 0.21); I² = 37%















Heterogeneity: Chi² = 12.42, df = 4 (P = 0.01); I² = 68%








Heterogeneity: Chi² = 15.95, df = 3 (P = 0.001); I² = 81%












Heterogeneity: Chi² = 16.14, df = 7 (P = 0.02); I² = 57%




















































































































































M-H, Fixed, 95% CI
2.27 [1.44 , 3.60]
1.52 [0.97 , 2.37]
1.91 [1.38 , 2.63]
1.42 [0.65 , 3.12]
1.42 [0.65 , 3.12]
4.99 [2.33 , 10.65]
1.33 [0.60 , 2.96]
1.42 [0.93 , 2.15]
2.91 [1.35 , 6.24]
1.23 [0.70 , 2.18]
1.94 [1.48 , 2.53]
0.93 [0.49 , 1.75]
1.22 [0.54 , 2.76]
4.89 [2.39 , 10.01]
4.00 [1.64 , 9.77]
2.31 [1.62 , 3.30]
2.20 [1.43 , 3.39]
5.37 [2.53 , 11.41]
2.56 [1.27 , 5.12]
1.97 [1.38 , 2.80]
1.18 [0.64 , 2.17]
1.14 [0.63 , 2.05]
6.50 [1.00 , 42.17]
1.60 [0.69 , 3.69]
2.14 [1.75 , 2.62]
0.63 [0.30 , 1.35]
0.63 [0.30 , 1.35]
Risk Ratio
M-H, Fixed, 95% CI
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Heterogeneity: Chi² = 35.73, df = 13 (P = 0.0007); I² = 64%

















































































0.63 [0.30 , 1.35]
2.20 [1.43 , 3.39]
0.79 [0.44 , 1.40]
5.18 [2.49 , 10.80]
2.27 [1.44 , 3.60]
1.63 [0.85 , 3.13]
1.52 [0.97 , 2.37]
1.42 [0.93 , 2.15]
3.90 [1.93 , 7.86]
4.00 [1.64 , 9.77]
1.97 [1.38 , 2.80]
1.18 [0.64 , 2.17]
1.19 [0.71 , 1.98]
6.50 [1.00 , 42.17]
1.60 [0.69 , 3.69]
1.99 [1.72 , 2.30]
0.1 0.2 0.5 1 2 5 10
Placebo better Levetiracetam better
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Analysis 1.7.   Comparison 1: Levetiracetam versus placebo, Outcome 7:










Heterogeneity: Tau² = 0.15; Chi² = 9.30, df = 4 (P = 0.05); I² = 57%












Heterogeneity: Tau² = 0.10; Chi² = 13.49, df = 7 (P = 0.06); I² = 48%


















Heterogeneity: Tau² = 0.11; Chi² = 28.93, df = 13 (P = 0.007); I² = 55%































































































































































M-H, Random, 95% CI
5.12 [2.40 , 10.92]
1.75 [0.78 , 3.91]
1.65 [1.09 , 2.50]
3.32 [1.48 , 7.45]
3.18 [1.62 , 6.23]
2.63 [1.67 , 4.14]
2.93 [1.85 , 4.65]
5.37 [2.53 , 11.41]
3.13 [1.52 , 6.45]
2.23 [1.54 , 3.24]
1.18 [0.64 , 2.17]
2.93 [1.48 , 5.80]
6.50 [1.00 , 42.17]
4.50 [1.18 , 17.21]
2.74 [1.96 , 3.82]
2.93 [1.85 , 4.65]
4.49 [1.94 , 10.39]
5.25 [2.52 , 10.94]
2.27 [1.44 , 3.60]
2.12 [1.07 , 4.20]
1.52 [0.97 , 2.37]
1.65 [1.09 , 2.50]
4.53 [2.14 , 9.57]
4.20 [1.73 , 10.20]
2.23 [1.54 , 3.24]
1.18 [0.64 , 2.17]
3.06 [1.60 , 5.83]
6.50 [1.00 , 42.17]
4.50 [1.18 , 17.21]
2.55 [1.99 , 3.27]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Placebo better Levetiracetam better
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Analysis 1.8.   Comparison 1: Levetiracetam versus placebo, Outcome 8: ≥ 50% reduction in focal seizure frequency:










Heterogeneity: Tau² = 0.22; Chi² = 12.42, df = 4 (P = 0.01); I² = 68%








Heterogeneity: Tau² = 0.64; Chi² = 15.95, df = 3 (P = 0.001); I² = 81%












Heterogeneity: Tau² = 0.12; Chi² = 16.14, df = 7 (P = 0.02); I² = 57%


















Heterogeneity: Tau² = 0.13; Chi² = 35.20, df = 13 (P = 0.0008); I² = 63%
























































































































































































M-H, Random, 95% CI
4.99 [2.33 , 10.65]
1.33 [0.60 , 2.96]
1.42 [0.93 , 2.15]
2.91 [1.35 , 6.24]
1.23 [0.70 , 2.18]
1.94 [1.17 , 3.21]
0.93 [0.49 , 1.75]
1.22 [0.54 , 2.76]
4.89 [2.39 , 10.01]
4.00 [1.64 , 9.77]
2.14 [0.89 , 5.11]
2.20 [1.43 , 3.39]
5.37 [2.53 , 11.41]
2.56 [1.27 , 5.12]
1.97 [1.38 , 2.80]
1.18 [0.64 , 2.17]
1.14 [0.63 , 2.05]
6.50 [1.00 , 42.17]
1.60 [0.69 , 3.69]
2.03 [1.45 , 2.84]
2.06 [1.33 , 3.18]
0.79 [0.44 , 1.40]
5.18 [2.49 , 10.80]
2.27 [1.44 , 3.60]
1.63 [0.85 , 3.13]
1.52 [0.97 , 2.37]
1.42 [0.93 , 2.15]
3.90 [1.93 , 7.86]
4.00 [1.64 , 9.77]
1.97 [1.38 , 2.80]
1.18 [0.64 , 2.17]
1.19 [0.71 , 1.98]
6.50 [1.00 , 42.17]
1.60 [0.69 , 3.69]
1.87 [1.45 , 2.41]
Risk Ratio
M-H, Random, 95% CI
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Analysis 1.8.   (Continued)
Test for overall effect: Z = 4.84 (P < 0.00001)
0.01 0.1 1 10 100
Placebo better Levetiracetam better
 
 
Analysis 1.9.   Comparison 1: Levetiracetam versus placebo, Outcome 9: ≥ 50% reduction
in focal seizure frequency: sensitivity analysis with trials of low risk of bias only
Study or Subgroup








Heterogeneity: Chi² = 14.08, df = 4 (P = 0.007); I² = 72%









Heterogeneity: Chi² = 12.52, df = 4 (P = 0.01); I² = 68%









Heterogeneity: Chi² = 14.70, df = 4 (P = 0.005); I² = 73%



































































































M-H, Fixed, 95% CI
2.59 [1.62 , 4.14]
5.18 [2.49 , 10.80]
1.48 [0.96 , 2.27]
4.45 [2.10 , 9.42]
4.00 [1.64 , 9.77]
2.93 [2.25 , 3.81]
2.93 [1.85 , 4.65]
5.25 [2.52 , 10.94]
1.65 [1.09 , 2.50]
4.53 [2.14 , 9.57]
4.20 [1.73 , 10.20]
3.13 [2.41 , 4.06]
2.20 [1.43 , 3.39]
5.18 [2.49 , 10.80]
1.42 [0.93 , 2.15]
3.90 [1.93 , 7.86]
4.00 [1.64 , 9.77]
2.69 [2.09 , 3.46]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Placebo better Levetiracetam better
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Analysis 1.10.   Comparison 1: Levetiracetam versus placebo, Outcome 10: ≥ 50% reduction in
focal seizure frequency: sensitivity analysis with trials of low risk of bias only (random e7ects)
Study or Subgroup









Heterogeneity: Tau² = 0.15; Chi² = 14.16, df = 5 (P = 0.01); I² = 65%










Heterogeneity: Tau² = 0.13; Chi² = 12.98, df = 5 (P = 0.02); I² = 61%










Heterogeneity: Tau² = 0.15; Chi² = 14.53, df = 5 (P = 0.01); I² = 66%


















































































































M-H, Random, 95% CI
2.59 [1.62 , 4.14]
5.18 [2.49 , 10.80]
2.27 [1.44 , 3.60]
1.48 [0.96 , 2.27]
4.45 [2.10 , 9.42]
4.00 [1.64 , 9.77]
2.81 [1.88 , 4.19]
2.93 [1.85 , 4.65]
5.25 [2.52 , 10.94]
2.27 [1.44 , 3.60]
1.65 [1.09 , 2.50]
4.53 [2.14 , 9.57]
4.20 [1.73 , 10.20]
2.95 [2.02 , 4.31]
2.20 [1.43 , 3.39]
5.18 [2.49 , 10.80]
2.27 [1.44 , 3.60]
1.42 [0.93 , 2.15]
3.90 [1.93 , 7.86]
4.00 [1.64 , 9.77]
2.65 [1.79 , 3.92]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Placebo better Levetiracetam better
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Heterogeneity: Chi² = 3.04, df = 1 (P = 0.08); I² = 67%















Heterogeneity: Chi² = 2.50, df = 4 (P = 0.64); I² = 0%








Heterogeneity: Chi² = 1.09, df = 3 (P = 0.78); I² = 0%











Heterogeneity: Chi² = 7.41, df = 6 (P = 0.28); I² = 19%















































































































































M-H, Fixed, 95% CI
0.48 [0.20 , 1.14]
1.49 [0.59 , 3.78]
0.80 [0.43 , 1.46]
2.96 [0.84 , 10.47]
2.96 [0.84 , 10.47]
1.94 [0.76 , 4.96]
2.00 [0.52 , 7.68]
1.14 [0.44 , 3.00]
0.85 [0.42 , 1.72]
1.21 [0.63 , 2.34]
1.23 [0.85 , 1.79]
1.30 [0.66 , 2.58]
2.33 [0.63 , 8.66]
1.34 [0.72 , 2.49]
3.00 [0.32 , 27.81]
1.49 [0.97 , 2.28]
1.24 [0.70 , 2.18]
1.25 [0.45 , 3.48]
3.33 [0.96 , 11.60]
0.44 [0.14 , 1.40]
0.33 [0.01 , 7.85]
1.09 [0.55 , 2.16]
0.33 [0.04 , 2.83]
1.11 [0.79 , 1.57]
0.92 [0.42 , 2.02]
0.92 [0.42 , 2.02]
Risk Ratio
M-H, Fixed, 95% CI
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Heterogeneity: Chi² = 12.00, df = 12 (P = 0.45); I² = 0%












































































0.92 [0.42 , 2.02]
1.24 [0.70 , 2.18]
1.12 [0.59 , 2.12]
1.59 [0.66 , 3.83]
0.48 [0.20 , 1.14]
2.66 [0.84 , 8.43]
1.49 [0.59 , 3.78]
1.14 [0.44 , 3.00]
1.09 [0.62 , 1.94]
3.00 [0.32 , 27.81]
0.44 [0.14 , 1.40]
0.33 [0.01 , 7.85]
1.15 [0.64 , 2.07]
0.33 [0.04 , 2.83]
1.11 [0.89 , 1.40]
0.02 0.1 1 10 50
More likely on PCB More likely on LEV
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Analysis 1.12.   Comparison 1: Levetiracetam versus placebo,







Heterogeneity: Chi² = 3.04, df = 1 (P = 0.08); I² = 67%















Heterogeneity: Chi² = 7.90, df = 10 (P = 0.64); I² = 0%
Test for overall effect: Z = 1.29 (P = 0.20)




















































































M-H, Fixed, 95% CI
0.48 [0.20 , 1.14]
1.49 [0.59 , 3.78]
0.80 [0.43 , 1.46]
1.24 [0.70 , 2.18]
1.12 [0.59 , 2.12]
1.59 [0.66 , 3.83]
2.66 [0.84 , 8.43]
1.14 [0.44 , 3.00]
1.09 [0.62 , 1.94]
3.00 [0.32 , 27.81]
0.44 [0.14 , 1.40]
0.33 [0.01 , 7.85]
1.15 [0.64 , 2.07]
0.33 [0.04 , 2.83]
1.18 [0.92 , 1.51]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
More likely on PCB More likely on LEV
 
 
Analysis 1.13.   Comparison 1: Levetiracetam versus placebo, Outcome







Heterogeneity: Tau² = 0.43; Chi² = 3.04, df = 1 (P = 0.08); I² = 67%
























M-H, Random, 95% CI
0.48 [0.20 , 1.14]
1.49 [0.59 , 3.78]
0.83 [0.28 , 2.52]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Placebo better Levetiracetam better
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Analysis 1.14.   Comparison 1: Levetiracetam versus placebo, Outcome 14:









Heterogeneity: Chi² = 1.14, df = 4 (P = 0.89); I² = 0%
Test for overall effect: Z = 1.33 (P = 0.18)







































M-H, Fixed, 95% CI
1.24 [0.70 , 2.18]
1.59 [0.66 , 3.83]
1.14 [0.44 , 3.00]
1.09 [0.62 , 1.94]
3.00 [0.32 , 27.81]
1.26 [0.90 , 1.76]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
More likely on PCB More likely on LEV
 
 
Analysis 1.15.   Comparison 1: Levetiracetam versus placebo, Outcome 15: Treatment









Heterogeneity: Tau² = 0.00; Chi² = 1.14, df = 4 (P = 0.89); I² = 0%
Test for overall effect: Z = 1.26 (P = 0.21)







































M-H, Random, 95% CI
1.24 [0.70 , 2.18]
1.59 [0.66 , 3.83]
1.14 [0.44 , 3.00]
1.09 [0.62 , 1.94]
3.00 [0.32 , 27.81]
1.24 [0.89 , 1.74]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Placebo better Levetiracetam better
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Heterogeneity: Chi² = 8.72, df = 11 (P = 0.65); I² = 0%

















Heterogeneity: Chi² = 20.66, df = 7 (P = 0.004); I² = 66%
































































































































































































































M-H, Fixed, 99% CI
1.60 [0.37 , 6.94]
1.36 [0.61 , 3.05]
1.43 [0.67 , 3.06]
2.01 [0.84 , 4.79]
1.79 [0.55 , 5.84]
1.59 [0.31 , 8.12]
3.00 [0.38 , 23.60]
2.32 [0.67 , 8.03]
2.71 [0.99 , 7.43]
1.00 [0.46 , 2.18]
0.60 [0.10 , 3.45]
2.08 [0.52 , 8.28]
Not estimable
1.62 [1.19 , 2.20]
0.32 [0.09 , 1.13]
Not estimable
1.06 [0.56 , 1.99]
Not estimable
0.28 [0.09 , 0.86]
1.81 [0.55 , 5.94]
0.45 [0.12 , 1.71]
1.64 [0.67 , 3.98]
1.25 [0.24 , 6.47]




0.85 [0.59 , 1.21]
Not estimable
6.42 [0.15 , 272.26]
2.52 [0.92 , 6.94]
3.36 [0.44 , 25.66]
1.16 [0.23 , 5.77]
0.80 [0.17 , 3.83]
2.00 [0.22 , 17.92]
1.58 [0.37 , 6.80]
1.75 [0.38 , 8.04]
0.57 [0.19 , 1.69]
7.00 [0.15 , 324.08]
1.22 [0.28 , 5.36]
Not estimable
1.54 [0.98 , 2.41]
Risk Ratio
M-H, Fixed, 99% CI
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Heterogeneity: Chi² = 11.79, df = 10 (P = 0.30); I² = 15%

















Heterogeneity: Chi² = 2.24, df = 5 (P = 0.81); I² = 0%

















Heterogeneity: Chi² = 9.98, df = 4 (P = 0.04); I² = 60%








































































































































1.54 [0.98 , 2.41]
2.07 [0.72 , 5.95]
1.46 [0.48 , 4.42]
1.26 [0.54 , 2.96]
2.88 [0.54 , 15.42]
Not estimable
1.20 [0.28 , 5.09]
Not estimable






1.53 [0.98 , 2.38]
0.23 [0.05 , 1.03]
0.49 [0.12 , 1.98]
0.60 [0.32 , 1.15]










0.72 [0.49 , 1.06]
0.01 0.1 1 10 100
More likely on PCB More likely on LEV
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Analysis 1.17.   Comparison 1: Levetiracetam versus placebo, Outcome 17:


















Heterogeneity: Tau² = 0.35; Chi² = 20.66, df = 7 (P = 0.004); I² = 66%

















Heterogeneity: Tau² = 0.20; Chi² = 9.98, df = 4 (P = 0.04); I² = 60%








































































































































M-H, Random, 99% CI
0.32 [0.09 , 1.13]
Not estimable
1.06 [0.56 , 1.99]
Not estimable
0.28 [0.09 , 0.86]
1.81 [0.55 , 5.94]
0.45 [0.12 , 1.71]
1.64 [0.67 , 3.98]
1.25 [0.24 , 6.47]




0.74 [0.38 , 1.47]
0.23 [0.05 , 1.03]
0.49 [0.12 , 1.98]
0.60 [0.32 , 1.15]










0.69 [0.35 , 1.36]
Risk Ratio
M-H, Random, 99% CI
0.01 0.1 1 10 100
Placebo better Levetiracetam better
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Heterogeneity: Chi² = 4.21, df = 3 (P = 0.24); I² = 29%
Test for overall effect: Z = 3.07 (P = 0.002)







Heterogeneity: Chi² = 1.12, df = 3 (P = 0.77); I² = 0%













Heterogeneity: Chi² = 9.67, df = 8 (P = 0.29); I² = 17%








Heterogeneity: Chi² = 1.04, df = 3 (P = 0.79); I² = 0%

















































































































































































M-H, Fixed, 99% CI
0.23 [0.05 , 1.03]
0.49 [0.12 , 1.98]
0.60 [0.32 , 1.15]
0.84 [0.40 , 1.76]
0.60 [0.39 , 0.92]
0.58 [0.02 , 21.86]
1.46 [0.08 , 27.43]
1.27 [0.23 , 7.07]
4.77 [0.10 , 219.51]
1.50 [0.43 , 5.26]
6.42 [0.15 , 272.26]
2.52 [0.92 , 6.94]
1.16 [0.23 , 5.77]
2.05 [0.23 , 18.38]
1.58 [0.37 , 6.80]
1.75 [0.38 , 8.04]
0.57 [0.19 , 1.69]
7.00 [0.15 , 324.08]
1.22 [0.28 , 5.36]
1.55 [0.95 , 2.51]
2.07 [0.72 , 5.95]
1.46 [0.48 , 4.42]
1.26 [0.54 , 2.96]
1.29 [0.49 , 3.42]
1.47 [0.90 , 2.40]
0.32 [0.09 , 1.13]
1.06 [0.56 , 1.99]
0.28 [0.09 , 0.86]
0.47 [0.12 , 1.76]
1.64 [0.67 , 3.98]
1.25 [0.24 , 6.47]
0.44 [0.10 , 2.00]
Risk Ratio
M-H, Fixed, 99% CI
 
Levetiracetam add-on for drug-resistant focal epilepsy (Review)









Cochrane Database of Systematic Reviews
 





Heterogeneity: Chi² = 17.52, df = 6 (P = 0.008); I² = 66%








Heterogeneity: Chi² = 1.44, df = 3 (P = 0.70); I² = 0%







Heterogeneity: Chi² = 0.96, df = 2 (P = 0.62); I² = 0%














Heterogeneity: Chi² = 8.22, df = 9 (P = 0.51); I² = 0%




















































































































1.25 [0.24 , 6.47]
0.44 [0.10 , 2.00]
0.78 [0.54 , 1.14]
1.89 [0.45 , 7.95]
1.14 [0.21 , 6.26]
2.15 [1.01 , 4.58]
1.28 [0.42 , 3.92]
1.76 [1.03 , 3.02]
2.44 [0.15 , 39.15]
2.05 [0.23 , 18.38]
0.95 [0.23 , 3.88]
1.37 [0.47 , 4.00]
1.60 [0.37 , 6.94]
1.36 [0.61 , 3.05]
1.43 [0.67 , 3.06]
1.79 [0.55 , 5.84]
3.08 [0.39 , 24.21]
2.32 [0.67 , 8.03]
2.71 [0.99 , 7.43]
1.00 [0.46 , 2.18]
0.60 [0.10 , 3.45]
2.08 [0.52 , 8.28]
1.57 [1.13 , 2.20]
0.005 0.1 1 10 200
More likely on PCB More likely on LEV
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Heterogeneity: Chi² = 0.14, df = 1 (P = 0.70); I² = 0%






Heterogeneity: Chi² = 0.13, df = 1 (P = 0.71); I² = 0%






Heterogeneity: Chi² = 2.13, df = 1 (P = 0.14); I² = 53%






Heterogeneity: Chi² = 1.06, df = 1 (P = 0.30); I² = 5%






Heterogeneity: Chi² = 0.11, df = 1 (P = 0.75); I² = 0%


















































































































M-H, Fixed, 99% CI
1.63 [0.63 , 4.26]
1.63 [0.63 , 4.26]
1.92 [0.56 , 6.60]
1.42 [0.27 , 7.42]
1.72 [0.64 , 4.63]
1.51 [0.46 , 4.96]
1.06 [0.12 , 9.24]
1.39 [0.49 , 3.93]
3.36 [0.44 , 25.66]
0.80 [0.17 , 3.83]
1.52 [0.47 , 4.94]
2.88 [0.54 , 15.42]
1.20 [0.28 , 5.09]
1.82 [0.62 , 5.33]
1.20 [0.37 , 3.85]
0.97 [0.30 , 3.19]
1.09 [0.47 , 2.50]
2.01 [0.84 , 4.79]
1.59 [0.31 , 8.12]
1.90 [0.88 , 4.09]
Risk Ratio
M-H, Fixed, 99% CI
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Analysis 1.19.   (Continued)
Subtotal (99% CI)
Total events:
Heterogeneity: Chi² = 0.10, df = 1 (P = 0.75); I² = 0%






Heterogeneity: Chi² = 0.25, df = 1 (P = 0.61); I² = 0%





















1.90 [0.88 , 4.09]
1.11 [0.45 , 2.74]
1.59 [0.31 , 8.12]
1.22 [0.55 , 2.69]
0.01 0.1 1 10 100
More likely on PCB More likely on LEV
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Heterogeneity: Chi² = 0.01, df = 1 (P = 0.92); I² = 0%





































































































M-H, Fixed, 99% CI
1.92 [0.56 , 6.60]
1.92 [0.56 , 6.60]
1.10 [0.30 , 3.95]
1.10 [0.30 , 3.95]
4.80 [0.68 , 34.14]
4.80 [0.68 , 34.14]
1.41 [0.25 , 7.85]
1.41 [0.25 , 7.85]
1.42 [0.27 , 7.42]
1.42 [0.27 , 7.42]
5.76 [0.37 , 90.86]
7.00 [0.15 , 324.08]
6.17 [0.66 , 57.79]
1.44 [0.28 , 7.29]
1.44 [0.28 , 7.29]
0.42 [0.08 , 2.19]
0.42 [0.08 , 2.19]
Risk Ratio
M-H, Fixed, 99% CI
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Test for overall effect: Z = 1.30 (P = 0.19)









Heterogeneity: Chi² = 5.64, df = 5 (P = 0.34); I² = 11%













































































































0.42 [0.08 , 2.19]
0.42 [0.08 , 2.19]
11.28 [0.26 , 495.63]
11.28 [0.26 , 495.63]
5.92 [0.14 , 255.98]
5.92 [0.14 , 255.98]
4.85 [0.11 , 216.99]
4.85 [0.11 , 216.99]
4.85 [0.11 , 216.99]
4.85 [0.11 , 216.99]
0.14 [0.00 , 6.77]
0.14 [0.00 , 6.77]
2.02 [1.11 , 3.66]
1.66 [0.68 , 4.05]
11.28 [0.26 , 495.63]
1.41 [0.25 , 7.85]
0.14 [0.00 , 6.77]
7.00 [0.15 , 324.08]
1.87 [1.19 , 2.95]
2.02 [1.11 , 3.66]
1.66 [0.68 , 4.05]
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Heterogeneity: Chi² = 0.22, df = 1 (P = 0.64); I² = 0%








Heterogeneity: Chi² = 5.39, df = 3 (P = 0.15); I² = 44%









































2.02 [1.11 , 3.66]
1.66 [0.68 , 4.05]
1.90 [1.16 , 3.11]
11.28 [0.26 , 495.63]
1.41 [0.25 , 7.85]
0.14 [0.00 , 6.77]
7.00 [0.15 , 324.08]
1.79 [0.59 , 5.41]
0.002 0.1 1 10 500
More likely on PCB More likely on LEV
 
 
A D D I T I O N A L   T A B L E S
 
Test Subscale Placebo (n = 11) Levetiracetam 3000 mg/
day (n = 13)
Verbal Fluency — Improved Improved
Time on Part A Improved ImprovedTrail Making Test
Time on Part B Improved Improved
Number of correct responses Improved Improved
Perseverative errors Improved Improved
Non-perseverative errors Improved Worsened
Number of categories Improved Improved
Wisconsin Card Sorting Test
Performance time Improved IMPROVEDa
Digit symbol — Worsened Improved
Digit span — Worsened Worsened
Reaction time for naming words Worsened Improved
Correct number of naming words Worsened Improved
Reaction time for naming colours Improved Improved
Stroop Color–Word Interfer-
ence Task
Correct number of naming colours Improved Worsened
Table 1.   Cognitive assessment as mean changes from baseline in variables on neuropsychological tests: Zhou 2008 
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Logic memory — Improved Improved
Delayed logical memory — Improved IMPROVEDa
Visual memory — Improved Improved
Delayed visual memory — Worsened Improved
Calculation — Worsened Improved
Table 1.   Cognitive assessment as mean changes from baseline in variables on neuropsychological tests: Zhou
2008  (Continued)




Test Subscale Placebo (n = 27) Levetiracetam 60 mg/kg/day (n
= 46)
Leiter-R AM Composite score Improved Improved
General memory Improved Improved
Visual memory Improved Improved
Verbal memory Improved Improved
WRAML-2
Attention/concentration Improved Worsened
Cognitive/social Improved ImprovedLeiter-R ERS
Emotions/regulations Improved Improved
Table 2.   Cognitive assessment as least square mean change from baseline (Leiter-R AM, WRAML-2, Leiter-R ERS):
Levisohn 2009 and Loge 2010 (children) 
Leiter-R AM: Leiter International Performance Scale-Revised Attention and Memory; Leiter-R ERS: Leiter International Performance Scale-
Revised, Examiner's Rating Scale; n: number of participants; WRAML-2: Wide Range Assessment of Memory and Learning-2.
aP < 0.1.
Note: results were for per-protocol population
 
 
Test Subscale n Placebo (n = 27) n Levetiracetam 60 mg/kg/
day (n = 46)
Activities 22 WORSENEDa 41 Worsened
Social 22 Worsened 41 Worsened





Total competence 19 Worsened 34 Worsened
Table 3.   Behavioural and emotional functioning assessment as least square mean change from baseline (CBCL and
CHQ-PF50): Levisohn 2009 and Loge 2010 (children) 
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Anxious/depressed Improved Improved
Withdrawn/depressed Improved Worsened
Somatic complaints Improved Improved
Social problems Improved Worsened
Thought problems Improved Worsened
Attention problems Improved Improved
Rule-breaking behaviour Improved Worsened
Aggressive behaviour IMPROVEDa WORSENEDa
Internalising syndromesb Improved Improved









Role/social–emotional/behavioural 27 Worsened 45 Improved
Behaviour 27 Worsened 45 Worsened
Mental health 27 Improved 45 Improved
CHQ-
PF50
Psychosocial summary 26 Improved 44 Improved
Table 3.   Behavioural and emotional functioning assessment as least square mean change from baseline (CBCL and
CHQ-PF50): Levisohn 2009 and Loge 2010 (children)  (Continued)
CBCL: Achenbach Child Behavior Checklist; CHQ-PF50: Child Health Questionnaire-Parent Form 50; n: number of participants.
aP < 0.05.
bInternalising syndromes contain the withdrawn/depressed, anxious/depressed, and somatic complaints scores.
cExternalising syndromes contain the aggressive behaviour and rule-breaking behaviour scores.
Note: results were for per-protocol population.
 
 
LevetiracetamSubscale Placebo (n = 81)
1000 mg/day (n = 80) 3000 mg/day (n = 85)
Overall QoL Improved Improved IMPROVEDa
Seizure worry Worsened IMPROVEDa IMPROVEDa
Emotional well-being Improved Worsened Worsened
Energy-fatigue Worsened Improved Worsened
Cognitive functioning WORSENEDa Improved Improved
Medication effects Worsened Improved Improved
Table 4.   Quality of life assessment as mean change from baseline (QOLIE-31): Cereghino 2000 
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Social function Worsened Worsened Improved
Health status Improved Improved Improved
Table 4.   Quality of life assessment as mean change from baseline (QOLIE-31): Cereghino 2000  (Continued)




Subscale Placebo (n = 11) Levetiracetam 3000 mg/day (n = 13)
Overall QoL Improved Improved
Seizure worry Improved Improved
Emotional well-being Improved Improved
Energy-fatigue Improved worsened
Cognitive functioning Worsened IMPROVEDa
Medication effects Worsened Improved
Social function Improved IMPROVEDa
Health status Improved Improved
Table 5.   Quality of life assessment as mean change from baseline (QOLIE-31): Zhou 2008 




LevetiracetamQoL domain Placebo (n = 89)
1000 mg/day (n = 92) 2000 mg/day (n = 81)
Health status IMPROVEDa IMPROVEDa IMPROVEDa
Role limitation due to memory problems Improved IMPROVEDa Worsened
Pain Worsened IMPROVEDa Improved
Cognitive functioning Improved Improved Improved
Emotional well-being Unchanged Improved Improved
Energy/fatigue Improved IMPROVEDa Improved
Social functioning Improved IMPROVEDa Improved
Role limitation due to emotional problems Improved Improved Worsened
Role limitation due to physical problems Improved IMPROVEDa Improved
Table 6.   Quality of life assessment as mean change from baseline (ESI-55): Shorvon 2000 
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Physical function Improved Worsened Improved
Overall QoL Improved Improved IMPROVEDa
Health perceptions Improved IMPROVEDa IMPROVEDa
Table 6.   Quality of life assessment as mean change from baseline (ESI-55): Shorvon 2000  (Continued)
ESI-55: Epilepsy Surgery Inventory Scale; n: number of participants; QoL: quality of life.
aP < 0.05.
Note: almost all participants provided information for each individual domain.
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Mental health Baseline 35 Not applicable 40 Not applicable 37 Not applicable
Mental health Overall dou-
ble-blind
28 –1.7 (worsened) 30 1.7 (improved) 28 3.5 (improved)
Physical health Baseline 29 Not applicable 37 Not applicable 34 Not applicable
Physical health Overall dou-
ble-blind
28 3.6 (improved) 30 0.8 (improved) 26 2.3 (improved)
Role functioning Baseline 33 Not applicable 38 Not applicable 35 Not applicable
Role functioning Overall dou-
ble-blind
28 –0.5 (worsened) 31 0.4 (improved) 27 2.3 (improved)
Table 7.   Summary of quality of life: mean change from baseline (ESI-55 scale): Betts 2000 
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A P P E N D I C E S
Appendix 1. CRS Web search strategy
1. Levetiracetam* or Levitiracetam* or Keppra AND CENTRAL:TARGET
2. MESH DESCRIPTOR Epilepsies, Partial EXPLODE ALL AND CENTRAL:TARGET
3. ((partial or focal) and (seizure* or epilep*)):AB,KW,MC,MH,TI AND CENTRAL:TARGET
4. #2 OR #3 AND CENTRAL:TARGET
5. #1 AND #4
6. (monotherap* NOT (adjunct* OR "add-on" OR "add on" OR adjuvant* OR combination* OR polytherap*)):TI AND CENTRAL:TARGET
7. #5 NOT #6
8. #7 AND >24/02/2015:CRSCREATED
Appendix 2. MEDLINE search strategy
The following search strategy is based on the Cochrane Highly Sensitive Search Strategy for identifying randomized trials published in
Lefebvre 2011.
1. (Lev?tiracetam? or Keppra).tw.
2. exp Epilepsies, Partial/
3. ((partial or focal) and (seizure$ or epilep$)).tw.
4. 2 or 3
5. (randomized controlled trial or controlled clinical trial or pragmatic clinical trial).pt. or (randomi?ed or placebo or randomly).ab.
6. clinical trials as topic.sh.
7. trial.ti.
8. 5 or 6 or 7
9. exp animals/ not humans.sh.
10. 8 not 9
11. 1 and 4 and 10
12. (monotherap$ not (adjunct$ or "add-on" or "add on" or adjuvant$ or combination$ or polytherap$)).ti.
13. 11 not 12
14. remove duplicates from 13
15. limit 14 to ed=20150224-20181126
16. 14 not (1$ or 2$).ed.
17. 16 and (2015$ or 2016$ or 2017$ or 2018$).dt.
18. 15 or 17
------------------
The search strategy below is the original MEDLINE strategy that was used for earlier versions of this review. It is based on the Cochrane
Highly Sensitive Search Strategy for MEDLINE as set out in Appendix 4b of the Cochrane Handbook for Systematic Reviews of Interventions
(version 4.2.4, updated March 2005) (Higgins 2005).
1. randomized controlled trial.pt.
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2. controlled clinical trial.pt.
3. exp Randomized Controlled Trials/
4. exp Random Allocation/
5. exp Double-Blind Method/
6. exp Single-Blind Method/
7. clinical trial.pt.
8. Clinical Trial/
9. (clin$ adj trial$).ab,ti.




14. exp Research Design/
15. or/1-14
16. (animals not humans).sh.
17. 15 not 16
18. levetiracetam.tw.
19. (epilep$ or seizure$ or convulsion$).tw.
20. exp Seizures/
21. exp Epilepsy/
22. 19 or 20 or 21
23. 17 and 18 and 22
Appendix 3. ClinicalTrials.gov search strategy
Interventional Studies | Epilepsies, Partial | Levetiracetam OR Keppra
Appendix 4. ICTRP search strategy
Condition: partial epilepsy OR focal epilepsy
Intervention: Levetiracetam OR Keppra
Recruitment status: all
W H A T ' S   N E W
 
Date Event Description
27 November 2018 New citation required but conclusions
have not changed
Conclusions are unchanged.
26 November 2018 New search has been performed Searches updated 26 November 2018; three new trials have been
included (Zheng 2009; Yagi 2010; Inoue 2015).
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H I S T O R Y
Protocol first published: Issue 1, 2000
Review first published: Issue 1, 2001
 
Date Event Description
5 October 2017 New search has been performed Searches updated.
13 August 2015 New search has been performed Added Inoue 2015 to Classification pending references. This su-
persedes previous reference N01221 and Yagi 2010 in Studies
awaiting classification.
24 February 2015 New citation required but conclusions
have not changed
No new relevant studies, conclusions remain unchanged
24 February 2015 New search has been performed Searches updated 24 February 2015.
24 March 2014 New search has been performed Searches updated. No new studies found.
13 September 2012 Amended Missing citation added Yagi 2010
12 August 2012 New citation required but conclusions
have not changed
Paediatric data has been incorporated into the update.
19 April 2011 New search has been performed Addition of seven new trials to the systematic review and meta-
analysis, published after the original 2001 review.
8 November 2009 Amended Published notes added.
23 September 2008 Amended Converted to new review format.
1 July 2005 New search has been performed The date of the latest search for evidence to the review is 1 July
2005, no new studies were identified.
In a previous update on 27 September 2002 we found one new
study which we included as published data of the study N138
(Ben-Menachem et al. Efficacy and tolerability of levetirac-
etam 3000 mg/d in patients with refractory seizures: a mul-
ticenter, double-blind, responder-selected study evaluating
monotherapy. European Levetiracetam Study Group. Epilepsia
2000;41(10):1276-83).
One study was also added to the 'Studies awaiting assessment'
section (Boon P et al. Dose-response effect of levetiracetam
1000 and 2000 mg/day in partial epilepsy. Epilepsy Research
2002;48(1-2):s77-89). This will be assessed for inclusion at a later
date.
 
C O N T R I B U T I O N S   O F   A U T H O R S
GKM, BC, SJN, and PD were involved in all stages of conducting and writing of this review, assessing trials for inclusion, extracting
data, assessing trials for bias, and evaluating the overall certainty of evidence. These steps were each conducted independently before
collaboration with any disagreements resolved by discussion with AGM. JH oversaw data analysis.
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D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
The original version of the review was published in 2001 (Chaisewikul 2001), and the review was last updated in 2012 (Mbizvo 2012).
Therefore changes have been made to the format and content of the methods and the review from the protocol and from the last update
to this version of the review, in line with current MECIR standards (MECIR 2012) and the Cochrane Style Manual (community.cochrane.org/
style-manual).
Previous versions of the review considered the inverse of the primary outcome, that is, the proportion of people who did not achieve 50%
or greater reduction in focal seizure frequency, termed 'non-responders.' This analysis was not deemed to be reflective of clinical practice
for the 2019 update so the analysis of 'non-responders' was not performed in the current review. The dose–response analysis was also
updated and simplified for this update. Additionally, this update investigated for the presence of publication bias using funnel plots.
The term 'partial' has been replaced by 'focal', in accordance with the most recent classification of epilepsies of the International League
Against Epilepsy (ScheGer 2017).
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